

Index

A

- Abortion, spontaneous, 176–178, 176t–177t, 242
Acetaldehyde, 30, 31t, 34
Acetylcholine, 55
ACH. *See* Air change per hour
ACS. *See* American Cancer Society
Acute lymphocytic leukemia (ALL), 224–225, 232t–235t, 243
Acute otitis media (AOM), 280
 evidence review, 293, 294t–306t, 307f, 300
ADA. *See* Americans with Disabilities Act
Adducts, 39
Adenocarcinoma, lung, 428t–433t, 443, 488, 491, 494–496
Adenoidectomy, 293, 296t, 300t, 303t, 306t, 308, 309, 400
Adenotonsillectomy, 292–293, 308, 400
Adenylyl cyclase (AC) activity, 50
Adolescent(s). *See also* Age factors; Child(ren)
 beliefs about acceptability of smoking to adults, 613
 exposure of
 breast cancer risk in adulthood, 469–470
 cognitive development, 170, 210–211
 cotinine level trends, 134t, 135, 136t, 606
 in home, 619
 lipid profiles, 57
 lung function, 393
 respiratory symptom prevalence, 329, 352
 in food service work, 612
 smoking restrictions and, 616, 626
Adsorption, 86, 89, 93, 97, 99, 107, 109
Adult(s)
 asthma in (*See* Asthma, in adults)
 cancer in (*See* Cancer, in adults)
 cardiovascular diseases in (*See* Cardiovascular disease)
 cotinine half-life in, 103, 104t–105t, 131
 exposure prevalence in
 cotinine level trends, 132, 133–134, 134t–135t, 135, 136t, 139
 in home, 138–139, 604
 in workplace, 136, 137, 138–139, 141–145
 health effects in, 19
 respiratory effects in (*See* Respiratory effects, in adults)
 respiratory illnesses in (*See* Respiratory illnesses, in adults)
 respiratory symptoms in (*See* Respiratory symptoms, in adults)
 sites of exposure of, 135–136
 smoking by
 and child exposure in home, 137, 138
 prevalence, 587, 612
African Americans. *See also* Racial and ethnic variations
 beliefs about secondhand smoke, 588, 589
 cotinine half-life in, 103
 cotinine level trends, 132, 134t–135t, 670
 in children, 137–138
 home smoking restriction prevalence, 619
 protein adduct levels, 112
 support for smoking restrictions, 589, 594
Age factors. *See also specific age group*
 in allergic sensitization, 376, 369–370
 in asthma in children, 289, 310, 327, 364, 366, 374
 in beliefs about acceptability of smoking, 613
 in beliefs about secondhand smoke, 588
 in breast cancer risk, 448–449
 in cotinine levels in serum, 133, 134t–135t, 136, 136t, 137–138
 in exposure prevalence, 136t, 137–138, 139
 in LRIs in children, 289, 292, 319
 in odor response, 531
 in respiratory symptoms in children, 310, 327, 329
 in support for smoking restrictions, 588–589, 589t–591t, 593t, 595t–597t
 in wheeze onset, 356, 364, 374
 in workplace smoking restriction coverage, 601, 605t
Air, indoor, as public good, 637
Airborne components of secondhand smoke. *See* Atmospheric markers; Secondhand smoke concentrations
Air change per hour (ACH), 88–92, 88f
Air cleaning systems, 86, 635–639, 640t
Air conditioning, in homes, 86, 91–92
Air contaminant(s)
 indoor
 assessment models, 96–99, 635–636
 concentrations, 85, 86, 88f
 mechanical control of, 86–92
 toxic, classification of secondhand smoke as, 584
Aircraft, 584–585
Air exchange, 87, 88, 88f, 89. *See also* Ventilation
 in homes, 92
Air exchange rate, 92, 93, 96, 97, 98f, 99
 and airborne contaminant concentrations, 88, 88f
 in exposure models, 96–97, 636
Air Force, 586

Note: t following a number refers to a Table; f following a number refers to a Figure.

- Air handling unit (AHUs), 87f, 88, 635
- Air monitoring, 18–19. *See also* Atmospheric markers
- Airports, 97, 631
- Air quality, smoking restrictions and, 631
- Air Resources Board (ARB) (Cal/EPA), 584
- Air ventilation, 86. *See also* Ventilation
- Airway, 47–49
 - development, 47, 251
 - function, 391
 - inflammation, mechanisms of, 49, 263–265, 528
 - obstruction, prevalence of, 555, 558–559, 561 (*See also* Chronic obstructive pulmonary disease)
 - structure, 47
- ALA. *See* American Lung Association
- Alcohol consumption, and breast cancer risk, 478
- Aldehydes, 31t, 44f
- ALL. *See* Acute lymphocytic leukemia
- Allergy. *See also* Atopy and specific type
 - in adults, 547
 - development of, 48, 51, 263–265, 375–385, 377t–379t, 381t–382t, 383f, 384f
 - conclusion, 385
 - implications, 385
 - nasal, and smoke irritation, 542
- ALSPAC study, 268, 289, 290
- Alveoli, 46, 529–530
- American Academy of Pediatrics, 623
- American Cancer Society (ACS), 579, 580
 - cancer prevention studies (*See* Cancer Prevention Study I; Cancer Prevention Study II)
- American College Health Association, 631
- American Heart Association, 579
- American Indians, 139, 594. *See also* Racial and ethnic variations
- American Legacy Foundation, 620
- American Lung Association (ALA), 579, 630, 631
- American Medical Association, SmokeLess States program, 580
- American Nonsmokers' Rights Foundation (ANR), 579–581, 581, 585, 631, 633–634
- American Society of Heating, Refrigerating and Air-Conditioning Engineers (ASHRAE)
 - on secondhand smoke, 638–639
 - standards, 89, 90f, 638, 639, 645, 647, 649–650
- American Stop Smoking Intervention Study for Cancer Prevention, 580–581
- Americans with Disabilities Act (ADA), 634
- American Thoracic Society, respiratory questionnaire of, 299
- 3-Aminobiphenyl (3AB), 39, 100, 112
- 4-Aminobiphenyl (4AB), 30, 31t, 37t, 100, 112
 - human uptake, 37t–38t
- Animal studies, 51
 - atherosclerosis, 58–62, 60t–61t, 62f
 - carcinogenesis, transplacental, 221
 - carcinogenicity of smoke, 33–34
 - cough and wheeze, 265
 - endothelial dysfunction, 55
 - free radicals, ischemic effects of, 62
 - LDL cholesterol, 57
 - lung development, 262, 263
 - lung immunologic response, 264, 528
 - myocardial infarction, 63, 63f
 - neural development, 170
 - oxygen processing, 59
 - platelet aggregation, 53, 54, 57
 - pre- and postnatal exposure, 50
 - respiratory effects in adults, 542
- ANR. *See* American Nonsmokers' Rights Foundation
- Antioxidants, 59, 62, 64
- AOM. *See* Acute otitis media
- Aorta, damage to, 55
- Apartment buildings. *See* Multiunit housing
- L-Arginine, 49, 54, 63
- ARIC Study, 527, 529, 530
- Army, 584, 624
- Aromatic amines, 30, 31t, 100
 - and breast cancer, 446
 - Hb adducts of, 39–40, 100, 112, 114
 - human uptake, 39–40
- L-Ascorbic acid, 42, 62
- ASHRAE standards, 89, 90f, 638, 647, 648–650
- Asia. *See also* specific country
 - lung cancer studies, 438t, 439, 440t–442t, 443
 - cancer in adulthood after childhood exposure, 430–433, 440t
 - spousal exposures, 434–435, 436t
 - workplace exposures, 435, 438–439, 438t
- Asian Americans, 619. *See also* Racial and ethnic variations
- Assessment (of exposure). *See* Secondhand smoke exposure assessment and Biomarkers
- Associations, causal. *See* Causal associations
- Asthma
 - in adults, 555–558
 - conclusions and implications, 558, 668
 - evidence synthesis, 558
 - etiologic studies, 556, 668
 - lung function decline in, 539, 544, 553–555, 557
 - morbidity studies, 555–556, 557
 - mortality study, 555
 - nasal symptom susceptibility in, 542
 - respiratory symptom susceptibility in, 539, 543, 547, 548t–549t
 - in children
 - age factors, 288–289, 310, 327, 329, 330, 366–368, 374
 - conclusions, 11, 14, 400
 - early wheeze and, 291
 - home exposures and, 617–618
 - implications, 401
 - incidence studies, 356, 360, 357t–362t, 363f, 363–364, 401
 - mechanisms, 47–48

prognosis studies, 356, 357t–362t, 363–364
 severity, 18, 355, 368, 369t–373t, 374, 562
 exposure reduction and, 370, 374
 classification of, 267
 definition of, 401, 555–556
 mechanisms of, 46–48
 onset of (*See* Asthma onset)
 prevalence of (*See* Asthma prevalence)

Asthma onset
 in adults, risk of, 555–556, 668
 in children, 310, 355–375, 401
 conclusions and implications, 375, 400–401
 evidence review, 356–370, 357t–362t, 363f, 365t–366t, 367f, 369t–373t
 evidence synthesis, 374–375

Asthma prevalence, 139
 in adults, 556
 in children, 139, 145, 310–355
 conclusion and implications, 355
 epidemiologic evidence, 310–329, 312t–318t, 320t–327t, 328f, 329, 353–354, 353t, 357t–362t, 363f, 364–367, 365t–366t, 367f
 evidence synthesis, 354–355, 374–375
 prenatal and postnatal exposure and, 329, 352–353
 under 11 years of age, 327, 354t

Atherosclerosis, 57–59. *See also* Coronary heart disease
 animal studies, 57–59, 60t–61t, 62f
 carotid intimal-medial thickness and, 509, 530
 mechanisms of, 52, 54, 57–59, 506
 conclusions, 64

Atherosclerosis Risk in Communities (ARIC) Study, 527, 529, 530

Atmospheric markers, 8, 85, 93–95, 125, 127. *See also specific marker*
 assessment models, 92–95, 635–636
 carcinogenic, 30–33, 31t–32t
 conclusions and implications, 99
 correlations among, 95, 95t
 in homes, 90, 140–141
 sensitivity of, 95, 96f

Atopy. *See also* Allergy and specific disorder
 development of, 263–265, 375–385, 377t–379t, 381t–382t, 383f, 384f
 conclusions, 385
 evidence synthesis, 384
 implications, 385
 mechanisms of, 48, 51
 and wheeze, 367–368, 374

ATP (adenosine triphosphate) production, 59

Attitudes, public. *See* Public attitudes

Australia
 coronary heart disease study, 509, 511
 hearing loss study, 309
 LRIs in children study, 289–290
 lung function in infants study, 391
 middle ear disease studies, 293, 308, 309
 respiratory symptom prevalence in children study, 352
 stroke studies, 527, 528t, 529

Australian National Health and Medical Research Council (NHMRC), 509, 521
 Austria, 370
 Avon Longitudinal Study of Pregnancy and Childhood (ALSPAC), 268
 LRIs in children, 289, 290

B

Banzhaf, John, III, 584
 B[a]P. *See* Benzo[a]pyrene

Bars
 exposure in, 143, 592, 594
 nicotine concentrations, 152, 154t–155t, 642–643, 642f, 643t
 smoking restrictions, 581, 582–583, 584
 compliance with, 605, 607–608
 economic impact, 613–615
 public support, 588, 589, 591t, 592, 593t
 smoking/nonsmoking areas, 642–643, 643t, 644f

Bar workers, 152, 582, 602–603, 605

Beaches, 634

Begg's test, 290

Behavioral development, 210, 211–220, 218t–219t, 243

Behavioral interventions, 621–624

Behavioral Risk Factor Surveillance System (BRFSS), 134

Beliefs. *See* Public attitudes

Benzene, 30, 32t, 95, 100
 human uptake, 34, 40t

Benzo[a]pyrene (B[a]P), 30, 98, 100, 113, 446
 in follicular fluid, 168
 human uptake, 34
 metabolism, 43, 44f

Berkeley (California), 578

Beta-carotene, 42, 59, 62, 518

Bias, 6, 11, 17, 20. *See also* Misclassification; Publication bias
 in breast cancer risk studies, 473–474, 477
 in lung cancer risk studies, 6, 439, 443–445, 487, 501
 in meta-analyses, 20–22
 in tobacco industry research, 23, 602

Bidi, 489

Bingo halls, 92, 602
 nicotine concentrations, 154, 156t–157t, 591

Biomarkers, 3, 17, 18–19, 85, 100–114, 130, 131–132, 431. *See also specific biomarker*
 carcinogenic, levels in humans, 34–42, 35t–39t
 conclusions, 114
 criteria for, 100
 definition of, 100
 evaluation of, 100–114
 national trends, 132–133, 133f, 134t–135t, 135, 135t
 as validation of questionnaires, 13, 115, 131

Birth defects. *See* Congenital malformations

Birth weight
 and child development, 204
 low (*See* Low birth weight)

Blacks. *See* African Americans
Bladder cancer, 30
Blue-collar workers. *See also* Occupation(s)
workplace smoking restriction coverage, 599, 604f
Boston (Massachusetts)
asthma incidence in children, 360
lung function in infants, 391
smoking restrictions, 581, 583, 633
Bowling alleys
nicotine concentrations, 154, 156t–157t, 605
smoking restrictions, 608, 610
BPDE-N2-dG, 43
Brachial artery, endothelial dysfunction in, 54–55, 56f, 515
Brain cancer, in children, 224, 238t–241t, 242
Brain development, 170, 180, 210
Breast cancer, 446–480, 483, 484
association with exposure, biologic plausibility of, 446–447, 478–479
case-control studies, 447, 454–455, 456t–465t, 464–470, 472–479
cohort studies, 447, 448–449, 450t–453t, 452–454, 472–473, 475–477
conclusions and implications, 480
evidence consistency, 472–477
evidence synthesis, 472
evidence temporality, 477
exposure sources and, 474–477
meta-analysis, 470–471, 471t, 472f–475f
mortality studies, 418t–419t, 447, 450t–453t
smoking and, 446–480
Breathlessness. *See also* Dyspnea
prevalence in children, 311, 355
evidence review, 327, 350t–351t, 352f, 353t
BRFSS. *See* Behavioral Risk Factor Surveillance System
British Medical Journal, 576–577
Broin v. Philip Morris Cos. (1994), 634
Bronchial hyperreactivity (BHR), 375, 543, 557
mechanisms, 47, 48, 49
Bronchial responsiveness, 401
Bronchiolitis, 268, 283, 288. *See also* Wheeze
Bronchitis
in children, 268, 283, 288–289, 290, 292
with wheeze, 356, 360, 367–368, 374
chronic, with COPD, 557, 558–559
Brookhaven National Laboratory, 90
Brown and Williamson Tobacco Company, 581
Buffalo (New York), 620
Building(s)
office, 641 (*See also* Office[s])
shared, 158 (*See also* Multiunit housing)
ventilation (*See* Ventilation)
Building automation system (BAS), 90–91
Building ventilation codes, 89
Buses, 632
Butadiene, 31, 34, 96
and atherosclerosis, 58

C

Cadmium, 32
Cafeterias, 145, 154, 641
Cal/EPA. *See* California Environmental Protection Agency
California
adult-onset asthma study, 543
breast cancer risk study, 466–467
classification of secondhand smoke as toxic air contaminant, 573t, 584
COPD study, 561
exposure prevalence study, 131
lung function studies, 392, 554
smoking restrictions, 576, 578–579, 582
compliance in bars, 607–608
economic impact, 613–615
health effects, 610–611
in homes, 616, 619, 625, 633–634
outdoor, 586, 587, 626, 627, 628, 629
in prisons, 628
public support for, 592
spontaneous abortion study, 177–178
California Environmental Protection Agency (Cal/EPA)
breast cancer study, 440
classification of secondhand smoke as toxic air contaminant, 584
coronary heart disease study, 509, 520
lung function in children study, 385
nasal sinus cancer study, 480
report on secondhand smoke (1997), 576
report on secondhand smoke (2005), 7, 29, 584
reproductive and perinatal effects study, 167, 169t
respiratory effects in adults study, 543
California Teachers Study, on breast cancer risk, 447, 453–454, 477
California Tobacco Survey, 137, 142, 611–612, 615
Canada
asthma in children study, 364, 368, 374
breast cancer studies, 458t–459t, 465–466, 479
lung cancer studies, 428t, 429t, 437t, 441t, 486–487
spousal exposures, 434–435, 486–487
workplace exposures, 435, 437t, 438, 486–487
lung function studies, 388t, 389t, 554
Cancer. *See also specific type*
in adults, 423–497
conclusions, 21–22, 483
association with exposure, evidence of, 6, 30–46, 423, 446, 483
conclusions, 45–46, 65
implications, 66
in children, 221–242
biologic basis, 221
conclusions, 242–243
epidemiologic evidence, 224–225, 226t–241t
implications, 242, 244
mechanisms (carcinogenesis), 42–45, 44f
transplacental, 221

- Cancer Prevention Study I (CPS-I), 512t, 519, 521, 523
 Cancer Prevention Study II (CPS-II), 449, 512t, 519, 521, 523
 Carbon monoxide (CO), 3
 as atmospheric marker, 93, 97
 as biomarker, 100–101, 102t–103t
 Carboxyhemoglobin, 100, 102t–103t
 Carcinogen(s), 30–33, 31t–32t, 65, 423, 443. *See also specific substance and type of cancer*
 airborne concentrations
 in casinos, 591
 in sidestream smoke, 31t–32t
 biologic concentrations
 in humans, 34–42, 35t–39t, 40t
 in mothers and infants, 220–221
 classification of secondhand smoke as, 6, 576, 577, 578
 conclusions, 45–46
 metabolism, 42–45
 non-tobacco, occupational exposure to, 426, 444
 Carcinogenesis, 42–45, 43f, 431
 transplacental, 221
 Cardiovascular disease, 509–532. *See also Atherosclerosis;*
 Coronary heart disease; Stroke
 averted, cost savings from, 616
 conclusions, 22, 532
 dietary and behavioral risk factors, in exposed versus unexposed persons, 502–505
 implications, 532
 risk of, 667
 Cardiovascular effects
 of exposure, 18, 63, 64, 576–577, 667
 of workplace smoking restrictions, 611
 Carotid intimal-medial thickness (IMT), 530
 Case-control studies. *See also specific condition*
 asthma
 in adults, 556, 557
 in children, 355–356, 358t–360t, 364, 365t–366t, 367f, 366–368
 breast cancer, 447, 454–470, 456t–465t, 472–479
 cancer in children, 224–225, 226t–241
 COPD, 559, 560, 561
 coronary heart disease, 509, 510t–513t, 511–513, 514t–517t, 515–521, 522t
 lung cancer, 427–434, 428t–433t, 486–497
 SIDS, 180–181, 182t–191t, 190
 stroke, 513, 514t, 515
 Casinos
 nicotine concentrations, 154, 156t–157t
 smoking restrictions, economic impact of, 613
 worker exposure, 154, 602, 604–605
 Cat allergy, 376, 379
 Causal associations, 10–11, 29
 classification hierarchy, 10, 10t
 confounding factors and, 22–23
 criteria for, 10
 evidence from active smoking and, 10–11
 meta-analyses and, 20–22
 Centers for Disease Control and Prevention (CDC), 132, 137, 620
 Guidelines for School Health Programs to Prevent Tobacco Use and Addiction, 630
 National Health Interview Survey (*See National Health Interview Survey*)
 School Health Policies and Programs Study, 630–631
 Central nervous system
 tumors, in children, 225, 238t–241t, 242
 Cervical cancer, 482–483, 484
 Cessation. *See Smoking cessation*
 C-fibers, lung, 48, 51, 528
 CHD. *See Coronary heart disease*
 Chengdu (China), breast cancer study in, 469
 Child(ren). *See also Adolescent(s); Age factors; Child exposures; Infant(s)*
 asthma (*See Asthma, in children*)
 asthma onset (*See Asthma onset, in children*)
 asthma prevalence (*See Asthma prevalence, in children*)
 atopy/allergy (*See Atopy*)
 bronchial hyperreactivity, 47
 cancer in (*See Cancer, in children*)
 cotinine in
 half-life, 101, 131
 levels, 133, 134t, 135, 136t, 137–138, 158, 620, 668
 saliva as matrix for, 107
 developmental effects (*See Child development; Fetal development*)
 health effects, 18, 576–577
 lipid profiles, 57
 lung development (*See Lung development*)
 lung function (*See Lung function, in children*)
 middle ear disease (*See Middle ear disease*)
 nasal and sinus disease, 51
 oxygen delivery dysfunction, 59
 protein adduct levels, 112–113
 respiratory effects (*See Respiratory effects, in children*)
 respiratory infection (*See Respiratory infection, in children*)
 respiratory symptoms (*See Respiratory symptoms, in children; specific symptom*)
 wheeze (*See Wheeze, in children*)
 young
 allergic sensitization, 376, 379–380
 exposure trends, 606, 667, 668
 interventions for, 620
 lower respiratory illnesses (*See Lower respiratory illnesses (LRIs), in young children and infants*)
 lung growth and function, 385
 wheeze, 265, 267, 356, 360, 363–364, 375, 401
 evidence review, 268–291, 269t–278t, 279t–281t, 282t, 284t–288
 mechanism, 265, 291–292
 Child development, 167, 169–170, 210–220. *See also Fetal development*
 behavioral effects, 210, 218t–219t, 220, 243
 biologic basis, 210

- cognitive effects, 170, 210–211, 212t–217t
- conclusions, 13, 167, 168t–169t, 652
- confounding factors, 210
- critical exposure periods, 169–171, 171t, 210
- epidemiologic evidence, 210–220, 212t–219t
- height/growth effects, 220, 222t–223t, 243
- Child exposures. *See also* Child(ren)
 - and breast cancer risk in adulthood, 449, 452–455, 464–465
 - and COPD risk, 50
 - in day care, 630
 - health effects, 19, 576–577
 - in home, 131, 133–134, 616
 - interventions to reduce, 620–621, 622t–625t, 624–625
 - prevalence, 133–134, 617, 618, 619
 - and lung cancer risk in adulthood, 436t, 439, 441t–442t, 485–497
 - and nasopharyngeal carcinoma in adulthood, 480
 - periods of, and developmental effects, 169–171, 167t, 210
 - pre- and postpartum, 136, 211
 - prenatal (*See* Prenatal exposure)
 - prevalence, 137–138, 136, 141
 - in home, 137–138, 617, 618, 619
 - trends, 132–133, 134t, 137–138, 652
 - in restaurants, 136, 145
 - in school, 630–631
 - sites of, 135, 136
 - young children, 620, 667, 668
- Children's Health Study, 380
- Chilum, 483
- China
 - atmospheric markers in homes, 141
 - breast cancer studies, 469–470, 477
 - cough in adults study, 535
 - LRI in children studies, 289–290
 - lung cancer studies, 434, 491–492, 493–496
 - nasopharyngeal carcinoma studies, 480–481
 - respiratory symptom prevalence in children study, 318–319, 352
 - vasodilation study, 55
- Chinese persons, outside of China
 - cotinine half-life in, 103
 - lung cancer studies, 434, 491–492
- Chongqing (China), breast cancer study in, 469–470
- Chromatography, 104t–105t, 106
- Chromium, 32
- Chronic obstructive pulmonary disease (COPD), 539, 543, 558–562
 - etiologic studies, 559–561
 - evidence synthesis, 561–562
 - implications and conclusions, 562
 - mechanisms, 49, 558–559
 - morbidity studies, 561
 - mortality study, 558–559
- Cigarette-years, 454
- Cigars, 97
- Civil Aeronautics Board (CAB), 572t, 585
- Clean Air Act of 1990*, 637, 638
- Clean indoor air laws. *See also* Smoking restriction policies
 - economic impacts, 580, 582, 613–616
 - effectiveness criteria, 609
 - history of, 571, 572t–574t, 576–578
 - local ordinances, 572t–574t, 576, 577–582
 - preemption laws and, 581–582
 - state, 572t–575t, 577–578, 579t, 582–584
- Clinton, William, 586
- Clotting, 53
- CO. *See* Carbon monoxide
- Cognitive development, 170, 210–211, 212t–219t
- Cohen, William, 586
- Coherence, 29
- Cohort studies. *See also specific condition*
 - asthma in adults, 557
 - asthma/wheeze onset in children, 355, 356, 357t–362t, 363f, 363–364, 374
 - atopy, 375–376, 379–380, 382, 384
 - breast cancer, 448–449, 450t–453t, 452–454, 472–473, 475–477
 - childhood cancer, 224
 - COPD, 561, 562, 563
 - coronary heart disease, 509, 510t–513t, 511–513, 514t–517t, 515, 517–521, 522t, 513–524, 524f–525f, 526f
 - low birth weight, 200t–204t
 - LRIs in children, 277
 - lung cancer, 423, 426–427, 426t–427t, 434–435, 436t, 485–486
 - lung function
 - in children, 385, 386t–390t, 393, 398
 - in infants, 391
 - middle ear effusion, 303, 308
 - recurrent otitis media, 300
 - sudden infant death syndrome, 190t–191t
 - stroke, 527, 528t, 529
- Colleges, 631
- Colombia, 561
- Colorado, 557, 582, 614
- Community Intervention Trial for Smoking Cessation (COMMIT), 587, 611
- Compliance (with smoking restrictions)
 - in hospitals, 626–627
 - in workplaces, 605, 607–608
- Components, secondhand smoke. *See* Atmospheric markers; carcinogens; secondhand smoke
- Conception delay, 171–172, 173, 174t–175t
- Confounding, 22–23
- Congenital malformations, 205–209
- Connecticut, 582
- Consistency, 472
- Controlled building ventilation, 88–89
- Control measures. *See* Secondhand smoke exposure control
- COPD. *See* Chronic obstructive pulmonary disease
- Coronary artery, endothelial dysfunction in, 55, 520
- Coronary Artery Risk Development in Young Adults Study, 111, 515

- Coronary flow velocity, 55, 56f, 520
- Coronary heart disease (CHD), 509–526. *See also*
- Atherosclerosis
 - conclusions, 11, 15, 64, 509, 532
 - epidemiologic evidence, 512–524, 514t–517t, 522t, 524f–525f, 526t, 526f
 - dose-response relationship, 515, 523–524, 526, 525f, 526t
 - evidence synthesis, 531
 - methodologic issues, 14, 512, 523
 - ischemic damage, 59, 62–63
 - mechanisms, 52–64, 65, 506
 - mortality, 509, 519–520, 532, 576, 611, 650
 - workplace smoking restrictions and, 611
- Correctional facilities, 150, 586, 628–629
- Cortical granule reaction, 172
- Cotinine
- in air passengers and flight attendants, 585
 - analytical (physiologic) matrices, 106–108
 - analytical methods, 103, 106, 106t
 - as biomarker, 13, 85, 100, 101–103, 106, 107–109, 110–112, 130, 131–132
 - in casino workers, 604–605
 - in children
 - age factors, 329
 - and asthma, 366–367
 - half-life of, 100, 131
 - with LRIs, 276
 - maternal smoking and, 354
 - national trends, 131, 132t, 133, 134t, 135–136, 606, 667
 - in sudden death, 181
 - dietary nicotine and, 109–110
 - factors affecting levels of, 106, 132
 - and fertility, 171
 - in hair, 108–109
 - half-life of, 101, 104t–105t, 131
 - and HDL cholesterol, 504
 - human uptake, 40–41, 42f
 - in infants, 99, 213, 376, 391
 - with SIDS, 177
 - and lung cancer risk, 443, 485–486
 - in maternal fluids, 181
 - metabolism, 103, 109, 112
 - national trends, 131–135, 133f, 134t–136t, 137–138, 139, 557, 606, 652
 - as nicotine exposure index, 110–112, 111t
 - and NNAL plus NNAL-Gluc, 40–41, 41t, 41f
 - in plasma, 107, 110–112, 111t
 - in restaurant workers, 599, 601, 603, 605
 - in saliva, 107–108, 110
 - of office workers, models assessing, 99
 - in serum, 106, 107, 110–111
 - smoking restrictions and, 610, 620, 621
 - in urine, 101, 106t
- Cotinine glucuronide, 101, 107
- Cotinine-creatinine ratios, 108
- Cough
- in adults, 539, 545, 547, 548t–552t, 549, 555
 - in children, prevalence of
 - conclusions, 355
 - epidemiologic evidence, 312t–318t, 326, 327, 329, 341f, 342t–349t, 353t
 - questionnaires, 311
 - under 11 years of age, 327, 354t
 - in young children, mechanism of, 265
- CPS. *See* Current Population Survey
- CPS-I. *See* Cancer Prevention Study I
- CPS-II. *See* Cancer Prevention Study II
- Creatinine, 108
- Cross-sectional studies. *See also specific condition*
- annoyance and irritation, 546
 - asthma in adults, 556, 557
 - atopic asthma/wheeze in children, 368
 - cardiovascular risk profile, 519, 531
 - COPD, 559
 - lung function
 - in adults, 554, 555
 - in children, 385, 386t–390t, 391–393, 394f–397f, 398
 - middle ear effusion, 300, 303
 - respiratory symptoms in adults, chronic, 546
 - stroke, 527, 529
- Cuban Americans, 650
- Current Population Survey (CPS), 140
- Tobacco Use Supplement, 587, 588–589, 592, 598–599, 601–603, 605, 611
- CYP1A1 gene, 230
- CYP genes, 43
- Cytochrome P-450 enzymes, 43
- Cytokines, in airway, 47–48, 263–264
-
- ## D
- Database, companion to Surgeon General’s report (2006), 8–9
- Day care, 630
- Day-years, 455
- Death
- infant, 179, 242 (*See also* Sudden infant death syndrome)
 - sudden, in children, 193
- Decay rates, 88f, 92, 636
- Delaware, smoking restrictions in, 574t–575t, 581, 582, 592, 609, 612, 615
- Denmark
- atopy in children study, 379t
 - childhood cancer study, 224
 - respiratory illness in children study, 268
- Department of Defense (DOD), 586
- Department of Health and Human Services (DHHS), 586, 588
- Department of Veterans Affairs (VA)
- hospitals, 626
 - nursing homes, 629

- Deposition, 86, 96–97, 108–109
rate of, 96
- Dermatitis, atopic, 380
- Developing countries, LRIs in children in, 291
- Development. *See* Child development
- DHHS. *See* Department of Health and Human Services
- Diet
in exposed *versus* unexposed persons
and coronary risk from smoke, 517–519
and lung cancer risk from smoke, 444
as nicotine source, 109–110
- Dilution ventilation, 85–88, 638, 646
- 7,12-Dimethylbenz[*a,h*]anthracene, 58
- 2,5-Dimethylfuran, 100
- Displacement ventilation, 88–89, 625
- DNA, damage to, 41–42, 45, 64. *See also* Genetic effects
- DNA adducts, 43, 45, 109–110
and breast cancer, 434
- DOD. *See* Department of Defense
- Dog allergy, 364, 369
- Dose, 18f, 85
- Dose-response relationship
asthma in children, 355, 366–367
asthma onset in adults, 556, 558
atopic disease in children, 370
breast cancer risk, 447, 450t–453t, 466, 472
carotid intimal-medial thickness, 530
coronary heart disease risk, 519, 523–524, 526t, 512f, 526
experimental studies and, 528
low birth weight, 199, 205
LRIs in children, 283
lung cancer risk, 417t, 439, 440t, 443, 488
lung function in adults, 555
nasal symptoms in adults, 542, 545
nasopharyngeal carcinoma, 480
respiratory symptoms
in adults, 547, 549, 552–553
in children, 327, 355
- Dust
and airway inflammation, 265
allergy, 376, 379
- Dyspnea. *See also* Breathlessness
in adults, 547, 548t–552t, 552, 553
- E**
-
- Ear infections. *See* Middle ear disease
- Early childhood. *See* Child(ren), young
- Economic costs
of smoking among military personnel, 586
of smoking restrictions in hospitality industry, 613–616
- Eczema, 367–368, 376, 380
- Education, public. *See* Public education
- Educational level. *See also* Socioeconomic status
and beliefs about health risks of secondhand smoke,
588, 589t
and support for smoking restrictions, 590t–591t, 592,
593t, 594, 595t–597t
and workplace smoking restriction coverage, 602, 607f
- EEFR (end-expiratory flow rate), in children, 393, 397f,
397t–399t, 398
- Egger's test, 290
- El Paso (Texas), smoking restrictions in, 614
- EMBASE search, respiratory illness in children, 266
- Emphysema, 539
with COPD, 558–560
- Endocrine system, fetal, 250–251
- Endometrial cancer, 438, 480
- Endothelial dysfunction, 55, 57, 64, 65, 506, 515
mechanisms, 52, 54–56, 53f, 56f
- Endotoxins, and airway inflammation, 252–253
- England. *See* United Kingdom
- Environmental Protection Agency (EPA)
air contaminant biomarker criteria, 100
Building Assessment, Survey and Evaluation Study, 649
educational programs for smoke-free homes, 136
and home exposures of children, 617, 619
on lung cancer, 435, 576
on lung function in children, 385
1992 report on secondhand smoke
classification of secondhand smoke as carcinogen, 6,
576, 578–579
conclusions of, 6–7
methodologic issues, 16
tobacco industry lawsuit against, 21, 576
on respiratory symptom prevalence in children, 310
“Environmental tobacco smoke,” 3, 9
- Enzyme-linked immunoassay, 106
- Eosinophilia, 264
- EPA. *See* Environmental Protection Agency
- Epithelial dysfunction, 49, 50, 543–544
- Erythropoietin, 188
- Esophageal cancer, 302
- Estrogen, 438, 470
- 3-Ethenyl pyridine, 94t, 95, 95f, 99
- Ethnicity. *See* Racial and ethnic variations; *specific group*
- 3-Ethyladenine, 41–42
- Ethylnitrosourea, 212
- Europe. *See also specific country*
lung cancer studies, 428t–431t, 434, 435, 437t–438t, 438,
487–491
bronchial hyperreactivity, 47
cancer in adult after childhood exposure, 415, 418,
420t–421t
spousal exposures, 426–427, 428t–431t
workplace exposures, 435, 436t–438t, 438–439
respiratory symptoms in children, 311, 326, 353–354
- Evaluation of Carcinogenic Risks to Humans: Tobacco Smoke
and Involuntary Smoking* (IARC, 2004), 577
- Evidence evaluation, classification of causal associations,
10, 10t
- Exercise ability, 59
- Experimental chambers, 99

Experimental studies. *See also* Animal studies; *specific condition*
 asthma morbidity in adults, 547, 557
 and dose-response relationships, 546
 lung function in adults, 553–554, 557
 respiratory symptoms in adults, 547, 548t–549t
 Exposure models, 96–99
 mass balance, 85–86, 96, 635–636, 637
 Exposure periods
 and developmental effects, 169–171, 171t, 210
 and reproductive effects, 169–171, 171t
 Exposure-response relationship. *See* Dose-response relationship
 Exposure sites, 12–13, 135–136, 154. *See also* *specific site*
 Eye irritation, 610

F

Fair Housing Act of 1992, 633
 Fecundability, 171–172, 173
 Federal Aviation Administration (FAA), 584–585, 631, 637
 Federal Bureau of Prisons, 586, 629
 Federal government
 facilities funded by, smoking restrictions in, 630
 facilities of, smoking restrictions in, 586
 smoking restrictions by, 578, 584–586, 637
 FEFR (forced expiratory flow rate), in infants, 391
 Fertility, 171–173, 174t–175t
 Fetal development. *See also* Child development
 airway, 47, 251
 and atopy, 251–253, 376
 carcinogens and carcinogenesis, 221
 cognitive, 210–211
 and congenital malformations, 105, 206t–209t, 208–209
 and COPD risk in adulthood, 560
 exposure prevalence during, 139–140
 immunological, 376
 intrauterine growth retardation, 168t–169t, 171t, 198
 low birth weight, 198–205, 243
 lung effects, 262–263, 267, 291, 292
 and SIDS, 179
 and spontaneous abortion, 170
 Fetal hypoxia, 170, 180, 198, 210, 262
 FEV₁ (forced expiratory volume in 1 second)
 in children, 392–393, 395f, 398t–399t
 in COPD, 560, 561
 decline, in adults with asthma, 543, 554–555
 Filtration, 636. *See also* Air cleaning systems
 Finland
 smoking restrictions effectiveness study, 642
 spontaneous abortion study, 177–178
 Flight attendants, 584, 585, 634
 Florida, smoking restrictions in, 574t, 582
Flue-Cured Tobacco Cooperative Stabilization Corp. v. The United States Environmental Protection Agency, 21, 576
 Food, as nicotine source, 109–110
 Food allergy, 376

Food service workers, 599, 601, 602–604. *See also* Restaurant workers
 Formaldehyde, 30, 31t, 34, 94
 FPM (fluorescing particulate matter), 95t, 95, 99
 sensitivity, 96f, 99
 Framework Convention on Tobacco Control, 667
 FRC, in infants, 390–391
 Free radicals, 32
 myocardial damage by, 59, 62–63
 Funnel plot, 21
 FVC (forced vital capacity), in children, 385, 394f, 396t–399t

G

Gaming venues, 591, 601–602, 623. *See also* Bingo halls; Casinos
 Gansu Province (China), lung cancer study in, 434, 492, 495–496
 Gas chromatography with mass spectrometric detection (GC–MS)
 for cotinine measurement, 104t–105t, 106
 for nicotine recovery from foods, 109–110
 for PAH-albumin adduct measurement, 34, 36
 Gases (in smoke)
 as atmospheric markers, 93–95 (*See also* Atmospheric markers)
 behavior of, 9, 636
 Gas-liquid chromatography (GLC), 106, 104t–105t
 GASP. *See* Group Against Smoking Pollution
 Gas phase, 33–34
 Gastric cancer, 488
 GC–MS. *See* Gas chromatography with mass spectrometric detection
 Gender variations
 beliefs about secondhand smoke, 588
 carotid intimal-medial thickness, 516
 COPD risk, 559
 coronary heart disease risk, 511
 cotinine half-life, 103
 exposure prevalence, 650
 cotinine level trends, 134t–135t
 home smoking restriction prevalence, 619
 lung cancer risk, 426, 434, 487–488, 489, 490, 491, 493, 496–497
 adults with childhood exposures, 423, 426, 428t–433t
 lung function in adults, 554
 nasopharyngeal carcinoma, 472
 support for smoking restrictions, 588–589, 589t–591t, 593t
 workplace smoking restriction coverage, 586, 587, 599, 602t, 603f
 General ventilation. *See* Dilution ventilation
 Generation rate, 96, 636
 Genetic effects
 atopy/allergy development, 376, 384
 brain development, 170

carcinogens in smoke, 41–45, 64, 443
lung immunology, 251, 376
myocardium, 62
Genetic factors, in breast cancer risk, 447
Germany
breast cancer risk study, 467–468
carcinogen uptake study, 39
lung cancer risk study, 489–491
Gestation. *See also* Fetal development; Pregnancy
periods of, 170
Gestational age, small for (SGA), 168t–169t, 171t, 198,
200t–204t
Glantz, Stanton, 580
GLC. *See* Gas-liquid chromatography
Glue ear, 292, 293, 308. *See also* Middle ear effusion
Glutathione S-transferase (GST), 43
Government workplaces, smoking restrictions in, 578,
585–586, 588
Group Against Smoking Pollution (GASP), 579, 585
Growth effects
height, 220, 222t–223t, 243
intrauterine growth retardation, 198
low birth weight, 198–205
GST. *See* Glutathione S-transferase (GST)
Guangzhou (China)
lung cancer study, 493
nasopharyngeal carcinoma study, 480–481
Guide to Community Preventive Services (2005), 609, 612, 613,
616, 620

H

Hair

cotinine in, 108–109, 114
nicotine in, 108–109
and preterm delivery risk, 195, 198
Hay fever, 367–368, 380, 382. *See also* Nasal allergies;
Rhinitis, atopic/allergic
Hb adducts. *See* Hemoglobin (Hb) adducts
HDL cholesterol, 53, 57, 58, 518
Health and Lifestyle Survey (United Kingdom), 517
Health care costs, 602
The Health Consequences of Involuntary Smoking (1986). *See*
Surgeon General's report (1986)
The Health Consequences of Smoking (1972). *See* Surgeon
General's report (1972)
The Health Consequences of Smoking (1975). *See* Surgeon
General's report (1975)
Health effects
of secondhand smoke exposure, 3, 4t–5t, 6, 8, 667, 668
conclusions, 3–8, 4t–5t, 6t, 18, 19–23
reports, 3–8, 7t
of workplace smoking restrictions, 610–611
Health Effects of Exposure to Environmental Tobacco Smoke
(Cal/EPA, 1997), 577
Healthy People 2010, 581, 582, 585, 587, 631
“Healthy smoker effect,” 556

Hearing loss, 392, 296t, 308–309
Heart disease. *See* Cardiovascular disease; Coronary heart
disease
Heart rate variability, 63
Heating, ventilating, and air conditioning (HVAC) systems,
86–88, 634
conclusions, 114, 668
in homes, 91–92
“Heating degree days,” 92
Height effects, 220, 222t–223t, 243
Helena (Montana), workplace smoking restrictions in, 611
Helling v. McKinney (1993), 629
Hemoglobin (Hb) adducts, 34, 39, 100, 112–113, 114
Heterocycles, 30
Hickerson, Carmen, 616
High-density lipoprotein cholesterol, 53, 58, 518
High-performance liquid chromatography (HPLC), 106,
106t
“Hill” criteria, 10
Hispanic Americans. *See also* Mexican Americans; Racial
and ethnic variations
beliefs about secondhand smoke, 588, 589
exposure prevalence, 650
home smoking restrictions, 619
protein adduct levels, 112–113
smoking during pregnancy, 139
support for smoking restrictions, 589, 590t, 594
workplace smoking restrictions coverage, 601, 605, 606f
Home(s)
as exposure site, 135, 169–171, 601
nicotine concentrations, 140–141, 141f, 142t–143t, 144f,
155f, 618
particle concentrations, 91–92, 94
size and age of, 91
smoking adults in, 137, 138–139
ventilation of, 91–92
Home-based interventions, 621, 624
Home exposures, 137, 154, 155, 158, 598. *See also* Spousal
smoking
in adolescents, 620
in adults, 138–139, 620
and birth weight, 198
and breast cancer risk, 448–449, 450t–453t, 452–455,
456t–465t, 464–480
of children, 135, 137–138, 598
interventions to reduce, 620–621, 622t–625t, 624–625
prevalence, 137–138, 617, 619, 621
and lung cancer risk, 427, 428t–433t, 434–435, 445,
485–497
and nasopharyngeal carcinoma, 481–482
prevalence, 137–141, 617, 619
international comparisons, 141, 144f
in susceptible populations, 139–140
Home smoking restrictions, 138, 154, 616–626
effectiveness criteria, 616
effects
on exposure, 620–621, 624–625
on smoking behavior, 625–626

- interventions to introduce, 620–621, 622t–625t, 624–625
 - in multiunit housing, 632–633
 - prevalence, 137, 617, 618t, 619t, 619
 - reasons for, 616–617
 - Hong Kong
 - atmospheric markers in homes, 141
 - diet of exposed versus unexposed women, 517–518
 - lung cancer study, 491, 493
 - respiratory symptom prevalence in children study, 319, 352
 - spontaneous abortion study, 177–178
 - Hospitality industry. *See also specific type of venue*
 - exposure potential in, 602–604
 - smoking restrictions
 - compliance with, 605, 607–609
 - economic impacts, 613–616
 - effects of, 609–613
 - opposition to, 579, 584, 589, 638
 - Hospitals, smoking restrictions in, 626–628, 637
 - public support for, 588–589
 - Hotels, 632
 - Hour-year, 481
 - Household(s). *See Home(s)*
 - Housing, 91
 - air exchange rate and, 92
 - multiunit, 91–92, 154, 618
 - HPB. *See 4-Hydroxy-1-(3-pyridyl)-1-butanone*
 - HPLC. *See High-performance liquid chromatography*
 - HVAC systems. *See Heating, ventilating, and air conditioning (HVAC) systems*
 - Hydrogen cyanide, 101
 - Hydroquinones, 33
 - Hydroxycotinine, 101, 107
 - 8-Hydroxydeoxyguanosine (8-OH-dG), 41, 62
 - Hydroxyphenanthrene, 34
 - 1-Hydroxyproline, 100
 - 3-Hydroxypropyl mercapturic acid, 41
 - 1-Hydroxypyrene, 34
 - 4-Hydroxy-1-(3-pyridyl)-1-butanone (HPB), 40, 107, 113
 - Hypoxia, fetal, 170, 198, 210, 250
- I**
-
- IARC. *See International Agency for Research on Cancer*
 - IgE. *See Immunoglobulin E*
 - Illinois, 575t, 581, 633
 - Immune function, 48, 49, 263–264, 265, 376
 - Immunoassay, 106
 - Immunoglobulin E (IgE), 544
 - and atopy in children, 263–264, 376, 379–380, 384
 - in infants, 48, 375–376
 - India
 - bronchial hyperreactivity study, 543, 557
 - lung cancer study, 496–497
 - Indoor air
 - contaminants (*See Air contaminant(s), indoor*)
 - as public good, 637
 - quality, with smoking restrictions, 609
 - Indoor environments, movement of smoke in, 85, 86–91
 - Infant(s)
 - bronchial hyperreactivity, 47
 - and cancer in childhood, 221, 243
 - carcinogen levels, 221
 - congenital malformations, 205–209
 - cotinine half-life in, 102–103
 - cotinine levels, 181, 190, 192–193, 376, 391
 - in homes with smoking restrictions, 606
 - in urine, 108
 - developmental effects, 20, 167, 168t–169t, 169–171
 - cognitive, 170, 210–211
 - exposure prevalence, 140
 - IgE levels, 47, 375–376
 - low birth weight, 167, 198–205, 243, 289
 - LRIs, 261, 267–292, 374 (*See Lower respiratory illnesses (LRIs), in young children and infants*)
 - lung function, 385, 390–392, 398–399
 - preterm, 263, 289, 391, 392
 - preterm delivery, 179, 194–198
 - respiratory function, 180, 263
 - SIDS in (*See Sudden infant death syndrome*)
 - wheeze, 289, 356, 363–364, 374, 375, 401
 - Infant deaths, 179, 242. *See also Sudden infant death syndrome*
 - infant mortality rate, 179, 242
 - Infection, 49
 - respiratory (*See Respiratory infection*)
 - Infertility, 170, 171–173, 174t–175t
 - Inflammation
 - airway, mechanisms of, 48, 49, 264–265, 542
 - in atherosclerosis, 52
 - changes, in adults, 542, 543, 544
 - in COPD, 49
 - particle-induced, 265
 - Inorganic compounds, carcinogenic, 30, 32t, 32
 - Institutional settings
 - exposure prevalence, 136, 154
 - smoking restrictions, 626–628
 - Interferon gamma (IFN- γ), 48
 - Interleukin-2 (IL-2), 48
 - Interleukin-4 (IL-4), 48
 - International Agency for Research on Cancer (IARC), 435, 487–488
 - on breast cancer risk, 447–448
 - on cancer risk, 6, 424t, 435, 577
 - carcinogen evaluations by, 30, 31t–32t, 33
 - International comparisons, of exposures “away from work,” 141, 144f
 - International Study of Asthma and Allergy in Childhood (ISAAC), 311, 319, 382, 384
 - Interstate Commerce Commission, 632
 - Interstate public transportation, 631–632
 - Interventions, to reduce home exposures of children, 620–621, 622t–624t, 624–625

Intrauterine growth retardation (IUGR), 188
"Involuntary smoking," 3, 9

Ireland

- hearing loss study, 296t
- smoking restrictions, 583

Iron workers, 30

Irritation, smoke, 539, 540t–541t, 545–546
mechanism, 51, 542–543

ISAAC. *See* International Study of Asthma and Allergy in
Childhood

Ischemic damage, 59–63

Italy

- asthma/wheeze in children study, 352, 367, 368
- carcinogen uptake study, 42
- COPD study, 559
- diet and behavior of exposed versus unexposed
women, 511
- respiratory symptom prevalence in children study, 329,
352

IUGR. *See* Intrauterine growth retardation

J

Japan

- breast cancer studies, 447, 448–449, 473, 477, 479
- cervical cancer study, 482–483
- COPD mortality study, 560
- diet of exposed *versus* unexposed women, 517–518
- lung cancer studies, 426–427, 434, 485, 496
- nasal sinus cancer study, 480
- workplace smoking restrictions study, 642

Johns Hopkins medical institutions, 626, 627, 641

Joint Commission on Accreditation of Healthcare
Organizations (JCAHO), 592, 626–628, 629

K

Kansas City, 617

Kentucky, 137, 592, 599, 616

Koop, C. Everett, 6, 667

Korea

- breast cancer risk study, 448
- lung cancer risk studies, 426–427, 434, 485
- respiratory symptom prevalence in children study, 329

K-ras gene, 45

L

Lactate, 59

Laws. *See also* Clean indoor air laws
preemption, 581, 582

Lawsuits

- against smoke exposure, 633, 634
- by tobacco industry, 15, 576, 577

LBW. *See* Low birth weight

LDL cholesterol, 53, 57, 58

Legal approaches, against smoke exposure, 624, 634–635

Leukemia, 224–225, 230, 231

- acute lymphocytic, 224–225, 230, 232t–235t
- carcinogens, 30, 32, 34
- childhood, 230

Lifestyle factors, 23

- and cardiovascular disease risk, 517–520
- and lung cancer risk, 436

Lipid metabolism, 57, 62f, 58

Lipopolysaccharide, 252–253

Liver cancer, 477

Local exhaust ventilation, 88, 89

Local ordinances (smoking restrictions), 572t–575t, 578–582,
579f. *See also specific locality*
economic impacts, 614–616
effectiveness criteria, 609–610
for multiunit housing, 632

Los Angeles County (California), 607–608

Louisville (Kentucky), 616

Lounges. *See also* Bars

- airport smoking, 97

Low birth weight (LBW), 179, 198–205, 243

- epidemiologic evidence, 198–199, 200t–204t, 204
LRIs in, 277

Low-density lipoprotein cholesterol, 57, 58, 59, 61t

Lower respiratory illnesses (LRIs). *See also* Asthma;

Respiratory infection

- in young children and infants, 261, 267–292, 374
age of child and, 288–289, 292
biologic basis, 291
combined LRIs/URIs, 272t, 283, 287t, 288t
community studies, 268, 269t–277t, 282t, 284t–285t
conclusions, 292, 561
confounding factors, 283, 284t–288t, 292
epidemiologic evidence, 267–291
evidence synthesis, 291–292
hospitalization studies, 268, 272t–273t, 277t–278t,
279f–281f, 282t, 283, 287t–288t, 288–289
implications, 292
and wheeze, 374–375

Lowe's Home Improvement Company, 587

Low-income households. *See also* Socioeconomic status
child exposures in, 137, 620

Lung cancer, 213

- carcinogens, 30, 34, 41
- mechanisms, 42–45, 411, 431
- mortality, 485, 603, 648
- reports linking to secondhand smoke, 571, 576–577
- risk of, 6, 10, 423–445, 485–496
in adults after childhood exposure, 426, 428t–433t,
436t
bias in studies, 14, 423, 439, 443–445, 475
and breast cancer risk, 447
case-control studies, 427–434, 428t–433t, 486–497

cohort studies, 423, 426–427, 426t, 436t, 485–486
 conclusions, 6t, 11, 411, 424t–425t, 445, 561
 dose-response relationships, 439, 440t, 443
 evidence synthesis, 439–445
 in high exposure workplaces, 603–605
 implications, 445
 methods, 423, 426
 pooled analyses, 434–435, 436t–438t, 437–439, 440t–442t
 spousal smoking and, 6, 423, 426–427, 434–435, 436t, 443, 444, 484, 485–496
 workplace exposures and, 426, 428t–433t, 434–435, 436t–438t, 438–439, 484, 601–602
 toxicologic evidence, 29, 31, 34, 35t, 39, 45
 Lung development, 6, 47, 50, 249, 385, 560–561
 and COPD in adults, 560
 immunological, in utero, 263–265, 376
 and LRIs in children, 291–292
 mechanisms, 47, 262–263, 268
 Lung function
 in asthma, 46–49, 543, 553–555
 in children, 46, 385, 386t–391t, 390–393, 394f–397f, 397t–398t, 398
 conclusions and implications, 399–400
 evidence synthesis, 398–399
 decline, in adults, 539, 540t–541t, 543, 544, 553–555
 with asthma, 543, 553–555
 conclusions and implications, 555, 668
 and COPD, 49, 560
 in infants, 46, 180, 263, 385, 390–391, 398–399
 with workplace smoking restrictions, 610–611
 Lymphoma, in children, 221, 224, 225, 226t–241t

M

Macrophage dysfunction, 49, 264
 Maine, 580, 582, 592, 633
 Mainstream smoke
 carcinogenicity of, 33
 and secondhand smoke, 10, 85
 Malls, support for smoking restrictions in, 588–589, 592, 594, 596t
 Marines, 586
 Markers. *See* Atmospheric markers; Biomarkers
 Maryland
 COPD mortality study, 560
 exposure prevalence study, 130–131
 stroke study, 513
 workplace smoking restrictions, 584
 Massachusetts, smoking restrictions in, 580–581, 582–583, 592
 economic impacts, 614, 615
 and exposure reduction, 610
 Mass balance model, 85, 86, 92, 96, 635–636
 and separation strategies, 630

Mass balance–steady-state equation, 635–636
 Maternal exposure
 before pregnancy, and fertility, 168t–169t, 169–170
 during pregnancy
 and aminobiphenyl-Hb adduct levels, 39
 and cancer in children, 224–225, 226t–241t, 242, 243
 and child development, 210–211
 and congenital malformations, 205–209, 206t–209t
 cotinine half-life in pregnant women and, 103
 and height/ growth of child, 220
 and low birth weight, 198–199, 200t–204t, 204–205
 and preterm delivery, 194–195, 196t–197t
 prevalence of, 140–141
 reproductive and developmental effects, 167, 168t–169t, 169–171, 171t
 and spontaneous abortion, 176–178, 176t–177t
 Maternal smoking. *See also* Parental smoking
 and acute otitis media, 293
 and asthma onset in children, 360, 361t–362t, 363–364, 363f
 and atopic wheeze, 367–368, 374
 and atopy, 375–376, 379–380, 381t–382t, 383f, 384
 and behavioral development, 211, 218t–219t, 220
 and breast cancer in adulthood, 449, 452
 and cancer in children, 221
 cessation of, and LRIs in children, 290
 and height of child, 220, 222t–223t
 and infant death, 179
 and LRIs in children, 268, 288–291
 and lung cancer in adulthood, 439, 489
 and lung function in children, 385, 390
 and nasal and sinus disease, 51
 before pregnancy, and fertility, 171–173, 174t–175t
 during pregnancy
 and acute otitis media, 293
 and after pregnancy, 140, 179, 180, 210, 290
 and asthma in children, 46–47, 360, 363–364
 and atopic wheeze in children, 367–368
 and atopy in children, 263–265, 375–376, 379–380, 381t–382t, 383f, 384
 and cancer in children, 221
 and child development, 210
 and congenital malformations, 205–209
 and fetal airway development, 47
 and infant death, 179
 and low birth weight, 198–205
 and LRIs in children, 288–291
 and lung development in utero, 262–263, 267, 291, 292, 385
 and lung function in children and infants, 47, 385, 390–393, 398–399
 and pregnancy complications, 194–195
 and preterm delivery, 179, 194–195
 prevalence of, 139
 reproductive and developmental effects, 167, 168t–169t, 169–171, 171t

- and respiratory illness in children, 401
- and respiratory symptom prevalence in children, 329, 352–353, 354
- and SIDS, 50–51
- and respiratory illness in children, 266, 401
- and respiratory symptoms in children, 315, 317, 352–353, 354
- and SIDS, 50–51, 180–181, 182t–190t, 190–194
- and smoking during pregnancy, 278
- and wheeze in children, 268, 356, 360, 361t–362t, 363–364, 363f
- Mayo Medical Center, 626
- McDonald's, 634
- Mechanical mixing, 87–88
- Medline search
 - exposure prevalence, 129
 - lung cancer, 423
 - respiratory effects in adults, 539
 - respiratory illness in children, 254
 - toxicology, 29
- MEFR (mid-expiratory flow rate), in children, 393, 396f, 397t–398t
- Men. *See also* Gender variations
 - beliefs about secondhand smoke, 588
 - cotinine half-life in, 103
 - exposure prevalence, 650
 - lung cancer risk from spousal smoking, 426–427, 435, 490–491
 - nasopharyngeal carcinoma risk, 480–482
 - support for smoking restrictions, 589
 - workplace smoking restriction coverage, 599
- Menopausal status, and breast cancer risk, 448–449, 466, 472, 476–477
- Meta-analysis, 6, 8, 20–22
 - asthma in children, 363–364, 365t–366t
 - atopy in children, 376, 380, 381t–382t
 - breast cancer risk, 470–471, 471t, 472f–475f
 - cancer in children, 221
 - coronary heart disease, 510t–516t, 513, 518–519, 522t, 523, 524f, 525f
 - definition of, 20
 - fertility and smoking, 172
 - LBW, 199, 204
 - LRIs in children, 267–292
 - lung cancer, 426, 434–435, 436t–438t, 440t–442t, 443, 445
 - lung function in children, 385, 393, 394f–396f, 398
 - middle ear disease, 292–309
 - publication bias in, 290–291
 - respiratory illness in children, 266–267
 - respiratory symptom prevalence in children, 310–355
 - wheeze in children, 268, 363–364
- Metabolic activation, 43
- Metabolic detoxification, 43
- Metals. *See* Inorganic compounds
- Methodology (of report), 11–17
- 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), 39t, 40–41, 40t–41t, 41f, 100, 113–114
 - in casinos, 604
 - metabolism, 43
- 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), 30, 113
 - human uptake, 37t, 39
 - metabolism, 43, 44f
 - respiratory effects, 46
- Mexican Americans. *See also* Hispanic Americans
 - exposure prevalence, 636
 - cotinine levels, 133, 134t–135t
- Microenvironment, 17–18, 85, 96
- Microenvironmental model, 17, 85, 93, 96
- Middle ear disease, 292–309
 - conclusions and implications, 309
 - evidence review, 293–308, 294t–306t, 307f
 - evidence synthesis, 309
- Middle ear effusion (otitis media with effusion [OME]), 292, 294t–306t, 300, 303, 307f, 308
- Military, smoking restrictions in, 586
- Minnesota Tobacco Document Depository, 577
- Miscarriage. *See* Spontaneous abortion
- Misclassification, 19–20, 130
 - breast cancer risk studies, 448
 - COPD studies, 561
 - coronary heart disease studies, 513, 515
 - LRIs in children studies, 271
 - lung cancer risk studies, 19, 439, 443–445, 486, 515
 - random versus systematic, 19
 - respiratory studies in adults, 539
- Mixing, air, 85, 86–87
- Models of exposure, 83, 84, 94–97, 635–636
 - mass balance, 83, 84, 94, 635–636
- Mortality
 - COPD, 546
 - coronary heart disease, 509, 519–520, 521, 576, 611, 650
 - lung cancer, 484, 493, 605, 650
 - neonatal, 176–178 (*See also* Infant deaths)
 - in nonsmokers, Cal/EPA report (1997) on, 576
- Mortality rate, infant, 179, 242
- Mothers
 - exposure of (*See* Maternal exposure)
 - smoking by (*See* Maternal smoking)
- Mucociliary function, 51, 539, 542, 543
- trans,trans*-Muconic acid, 34, 39t
- Multiunit housing, 91, 92, 154, 632
- Myocardial infarction, 63, 63f, 511–512. *See also* Coronary heart disease
 - averted, savings from, 616
- Myocardium, damage to, 59, 62
- Myosmine, 95t, 95, 96f, 99

N

- N-Acetyltransferase 2* genotype (NAT2), 447
- nAChRs. *See* Nicotinic acetylcholine receptors (nAChRs)
- Nader, Ralph, 572
- 2-Naphthylamine, 30
- Nasal allergies, 546. *See also* Hay fever; Rhinitis, atopic/allergic
- Nasal and sinus disease, 51
- Nasal irritation, 51, 540t, 542, 545–546, 610
- Nasal mucociliary function, 51, 542, 544
- Nasal sinus cancers, 30, 472–474
- Nasopharyngeal carcinoma (NPC), 480–482, 484
- NAT2 genotype, 455
- National Cancer Institute (NCI), 576
 - American Stop Smoking Intervention Study for Cancer Prevention, 580
 - on flight attendant exposure, 585
 - Tobacco Use Supplement to Current Population Survey, 587, 588, 598–599, 602, 605
 - on workplace smoking restrictions and smoking behavior, 612
- National Center for Health Statistics, 132
- National Health and Nutrition Examination Survey (NHANES), 132
 - diet and behavior in exposed women, 517
 - exposure prevalence data
 - adults, 139, 143
 - children, 136t, 137–138, 604
 - cotinine measurements, 132–133, 133f, 134t–136t, 135, 137–138
- National Health and Nutrition Examination Survey, Third (NHANES III), 132, 134t–135t, 138, 518
 - acute LRIs in children, 268, 288, 289, 290
 - COPD in nonsmokers, 559
 - exposure prevalence data, 131, 634
 - adults in home, 139
 - children in home, 137, 138
 - cotinine measurements, 131, 132, 133, 134t–135t, 138, 560
 - public places, 145
 - regional differences, 155
 - women of childbearing age, 140
 - workplaces, 136, 142–143, 423, 602–603
 - lung function in children, 393
- National Health Interview Survey (NHIS)
 - chronic respiratory disease exacerbation, 557, 561
 - exposure prevalence, 137, 650
 - home exposures, 138, 617
 - in children, 137, 620
 - LBW, 189, 194
 - public attitudes toward secondhand smoke, 588
 - smoking prevalence in adults, 586, 617
 - workplace smoking restrictions, 598–599, 601–602
- National Human Activity Pattern Survey (NHAPS), 17, 135–136, 145
- National Mortality Followback Survey (NMFS), 506–507
- National Report on Human Exposure to Environmental Chemicals*, 132
- National Research Council (NRC)
 - on aircraft air quality, 572
 - on atmospheric markers, 93
 - on lung cancer, 6, 20, 445, 576, 578
- National Survey of Worksite Health Promotion Activities, 587
- National Toxicology Program, *9th Report on Carcinogens* (USDHHS 2000), 64, 571
- Navy, 586
- NCI. *See* National Cancer Institute
- Neonatal mortality, 176–178. *See also* Infant deaths
- Netherlands, lung cancer risk study, 426–427, 444–445, 485–486
- Neural dysfunction
 - in lung C-fiber CNS reflex, 48, 51
 - perinatal exposure and, 170, 210
 - and SIDS, 50–51
- Neuroendocrine cells, in lung, 47
- Neutrophilia, lung, 253
- New York
 - annoyance and irritation studies, 546
 - breast cancer risk studies, 468–469
 - smoking restriction laws, 580, 582, 592, 608, 632
- New York City, smoking restrictions in, 581, 583, 607, 608, 609, 612, 614, 615
- New Zealand
 - asthma incidence in children study, 356, 363
 - behavioral development study, 211, 212t–219t, 220
 - coronary heart disease study, 497
 - LRIs in children study, 288–289
 - respiratory symptom prevalence in children study, 329
 - stroke study, 531
- NHANES. *See* National Health and Nutrition Examination Survey
- NHANES III. *See* National Health and Nutrition Examination Survey, Third
- NHAPS. *See* National Human Activity Pattern Survey
- NHIS. *See* National Health Interview Survey
- NHS. *See* Nurses Health Study
- NHS-II. *See* Nurses Health Study II
- Nickel, 32
- Nicotine, 40
 - adsorption of, 86
 - airborne concentrations, 130
 - in bars, 154, 156t–157t, 605
 - in cafeterias, 145, 154
 - in homes, 140–141, 141f, 155f, 621
 - in nonsmoking areas near smoking areas, 644–645
 - in offices, 143–144, 155f
 - models assessing, 97
 - with smoking / nonsmoking areas, 644–646
 - by smoking policy type, 146t–147t, 148f, 646–647, 648f, 649
 - in prisons, 629

- in public places, 154, 156t–157t
 - with smoking bans, 641
 - and respirable particle concentrations, 93–94
 - in restaurants, 145, 152t–153t, 155f
 - in smokers' homes, 140–141, 141f, 142t–143t, 155f
 - in smoking areas, 644
 - in workplaces, 140, 143–145, 146t–151t, 148f, 149f, 155f
 - high exposure, 603
 - by smoking policy type, 646–647, 648f, 649
 - with smoking restrictions, 609–610, 641
 - and airway development, 47
 - and atherosclerosis, 58
 - as atmospheric marker, 12, 85, 93, 95, 96f
 - correlation with other atmospheric markers, 93–95, 95t, 96
 - sensitivity, 95, 96f
 - biological concentrations
 - dietary sources, 109–110
 - and fertility, 168
 - in hair, 108–109, 114, 195, 196t–197t, 199
 - in infants, 221
 - and LBW, 198–199
 - in lung, and SIDS, 50–51
 - and lung development, 47, 250
 - and myocardial function, 63
 - and neural development, 170, 210
 - and platelet function, 54
 - respiratory effects, 46, 47, 48, 50
 - and SIDS, 50–51, 180
 - and spontaneous abortion, 177–178
 - as biomarker, 17, 100, 101, 103, 108–113
 - exposure to, cotinine levels as index of, 11–112, 111t
 - metabolism, 103, 109
 - metabolites, 100, 107, 109 (*See also specific metabolite*)
 - in sidestream smoke, 101
 - Nicotinic acetylcholine receptors (nAChRs), 47, 48, 50, 262
 - Nigeria, 366
 - 9th Report on Carcinogens (USDHHS 2000), 577
 - Nitric oxide (NO)
 - and airway impairment, 48
 - in endothelial-dependent vasodilation, 54
 - exhaled levels in adults, 544
 - Nitrogen-phosphorus-specific detectors, 105t, 106
 - Nitrosamines, 30, 31t, 32
 - as atmospheric markers, 93
 - as biomarkers, 100, 113–114
 - tobacco-specific, 30, 113
 - in cervical mucus, 195
 - human uptake, 39–41
 - N-Nitrosodimethylamine, 30, 93
 - N'-Nitrosornicotine (NNN), 30, 40
 - N-Nitrosopyrrolidine, 30, 95
 - NNAL. *See* 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol
 - NNAL-glucuronide (NNAL-Gluc), 40–41, 41t, 42f, 113
 - NNK. *See* 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone)
 - No Child Left Behind Act of 2001, 586, 630
 - Non-Hispanic blacks. *See* African Americans
 - Non-Hispanic whites. *See* Whites
 - Non-Hodgkin's lymphoma, 224, 225, 234t
 - Nonsmokers. *See also* Smoking status
 - misclassification of, 20
 - presence of, and home smoking restriction prevalence, 616, 619
 - Nonsmokers' rights movement, 579
 - Nonsmoking areas
 - in aircraft, 585
 - in bars, 642–644, 642f, 643t
 - in offices, 644–645
 - in restaurants, 145, 152t–153t, 643, 644
 - Nonsmoking homes. *See* Home smoking restrictions
 - North Carolina
 - breast cancer studies, 454, 467
 - infant exposure study, 133
 - preemption law, 581
 - support for restaurant smoking bans, 592
 - workplace smoking restrictions coverage, 599
 - Norway, 329
 - NRC. *See* National Research Council
 - Nucleus tractus solitarius, 51
 - Nurses Health Study (NHS), 486, 519
 - Nurses Health Study II (NHS-II), 447, 449, 452–453
 - Nursing homes, 615–616
-
- O**
- Observational studies. *See also specific condition*
 - asthma morbidity, 559–560
 - building-related illnesses, 545–546
 - lung function decline in adults, 553–555
 - methodologic concerns with, 16–17
 - nasal irritation, 545–546
 - respiratory symptoms in adults, 547, 549, 550t–551t, 552–553
 - Occupation(s). *See also specific occupation*
 - exposed to PAHs, 30
 - with high exposure potential, 602–605
 - and support for smoking restrictions, 587, 589, 560t, 591t, 592, 593t, 595t–597t
 - and workplace smoking restrictions
 - compliance, 608t
 - coverage, 142, 586, 587, 598–602, 604f
 - Occupational exposure. *See* Workplace exposure
 - Occupational Safety and Health Administration (OSHA), 585–586, 626, 637
 - Ochner Clinic, 628
 - Odor annoyance, 539, 540t, 545–546
 - Office(s). *See also* Workplace(s)
 - exposures in, 649–650
 - nicotine concentrations, 143–145, 156f
 - models assessing, 97
 - in smoking/nonsmoking areas, 644, 645

by smoking policy type, 146t–149t, 148f, 646–647, 648f
 particulate matter, by smoking policy type, 647, 648f
 Office on Smoking and Health, 9
 8-OH-dG. *See* 8-Hydroxydeoxyguanosine
 OME (Otitis media with effusion). *See* Middle ear effusion
 O⁶-methylguanine, 43
 Oral clefts, 205, 206t–209t, 208–209
 Oregon, smoking restrictions in, 580, 617, 630–631
 Organic compounds. *See also specific substance*
 as atmospheric markers, 95
 carcinogenic, 30, 32t
 OSHA. *See* Occupational Safety and Health Administration
 Otitis media
 acute, 292, 293, 294t–306t, 307f, 397
 with effusion (*See* Middle ear effusion)
 recurrent, 292, 293, 294t–306t, 300, 307f
 Outdoor air
 as public good, 637
 in ventilation systems, 89–90, 90t
 Outdoor smoking restrictions, 586, 587, 633–635
 in California, 584, 633–634
 Oxidative stress, 41, 50, 52
 Oxygen delivery and processing, myocardial, 59

P

Pack-years, 441, 482
 PAF-AH. *See* Platelet-activating factor acetylhydrolase
 PAHs. *See* Polycyclic aromatic hydrocarbons
 Papirosy, 480
 Parental smoking. *See also* Child exposures; Maternal smoking; Paternal smoking
 and asthma in children, 355–375
 prevalence, 310–355
 severity, 368, 369t–373t
 and atopy in children, 375–385
 and breast cancer risk in adulthood, 450t–451t, 455, 456t–465t, 464, 468, 470, 475–476, 479
 and cancer in children, 221, 224–241, 226t–241t
 and congenital malformations, 205–209, 206t–209t
 and cognitive development, 212t–217t
 and fertility, 173
 and hearing loss, 308–309
 and height/growth of child, 220, 222t–223t
 and infant death, 179
 interventions to stop, 606, 608–611
 and low birth weight, 198, 199, 200t–204t
 and LRIs in children, 267–292, 290–291
 and lung cancer risk in adulthood, 436t, 439, 441t–442t, 485–496
 and lung function in children, 6, 18, 385–390
 and middle ear disease, 292–309
 and nasopharyngeal carcinoma risk in adulthood, 481–482

past, and respiratory symptom prevalence in children, 353
 prevalence of, 137, 138
 and respiratory illness in children, 261, 266, 401
 and respiratory symptom prevalence in children, 8, 310–355
 and SIDS, 180–194, 182t–191t
 and spontaneous abortion, 176–178, 176t–177t
 and wheeze, 291–292
 in infants, 289, 356–357, 374, 375
 Particle Total Exposure Assessment Study, 97, 99
 Particulate matter (PM), 3, 91, 93–96, 99
 behavior of, 3, 97
 concentrations, models assessing, 96–97, 635–636
 fluorescing (FPM), 95t, 95, 96f, 99
 in homes, air conditioning and, 91–92
 and inflammation, 253
 in offices, by smoking policy type, 647, 648f
 respirable (RPM) (*See* Respirable particulate matter)
 respirable suspended particles (RSP), 97, 98t
 in restaurants and bars, with smoking restrictions, 603–604
 ultraviolet-absorbing (UVPM), 94t, 95, 96f, 96, 99
 Particulate phase, 32
 “Passive smoking,” 9
 Paternal smoking. *See also* Maternal exposure; Parental smoking
 and asthma onset in children, 348, 349t–350t
 and breast cancer in adulthood, 452, 454, 481
 and cancer in children, 224–225, 226t–241t, 242, 243
 and congenital malformations, 205, 206t–209t, 208–209
 and fertility, 170–173
 and height, 220, 222t–223t
 and infant death, 179
 and low birth weight, 198, 199, 200t–204t
 and LRIs in children, 277–279
 and lung cancer in adulthood, 428t–433t, 439, 479, 489
 and respiratory illness in children, 266, 401
 and respiratory symptoms in children, 327, 354–355
 and SIDS, 180–181, 182t–191t, 190–192, 193–194
 and spontaneous abortion, 176–178, 176t–177t
 Pediatricians, 611
 Penetration coefficient, 635–636
 Perinatal effects, 167–244. *See also* Child development; Fetal development; Reproductive effects
 conclusions, 167, 168t–169t
 by exposure period, 169–171, 171t
 Personal diary, 131
 Personal monitors, 131, 143
 P53 gene, 43–45
 Phenanthrene, 38
 Phlegm
 in adults, 547, 549, 550t–552t, 553, 559–560
 in children, prevalence, 311, 355
 evidence review, 326–327, 350t–351t, 352f, 353t
 Physician-based interventions, 606, 610

- Physicians, 611, 621, 634, 669
- Piston flow. *See* Displacement ventilation
- Pittsburgh (Pennsylvania), middle ear effusion (OME)
study in, 303, 308
- Platelet-activating factor acetylhydrolase (PAF-AH), 54
- Platelet aggregation
in atherosclerosis, 57
in exposed nonsmokers versus smokers, 53–54, 53f, 506
mechanism, 52, 53–54
- Plug flow. *See* Displacement ventilation
- Plume (of cigarette smoke), 87
- PM. *See* Particulate matter
- Pneumonia, in children, 268, 283, 288–289
- Policy approaches, 154, 585–621, 655. *See also* Smoking
restriction policies
- Polycyclic aromatic hydrocarbons (PAHs), 31t, 32–34,
99–100, 112, 609, 636
and atherosclerosis, 58
and breast cancer, 434
levels in humans, 35t–39t, 39–41
in restaurants and bars, with smoking restrictions, 609
in smoke, 31t
- Polymorphonuclear leukocyte (PMN) counts, 49
- Population exposures, assessment methods, 85, 129–132.
See also specific method
- Populations, susceptible to exposure, 139–140, 670
- Postmenopausal women, breast cancer risk in, 448–449,
450t–453t, 452–454, 456t–465t, 466–470, 475f, 477–478, 479
- Postnatal exposure. *See also* Child(ren); Child exposures;
Infant(s)
in postpartum period, 167, 168t–169t, 221
and prenatal exposure, 140, 221, 290
prevalence of, 140
- Postpartum exposure, 167, 168t–169t, 221. *See also* Infant(s)
³²P-postlabeling, 41
- Preconception exposure, 169–171, 171t
- Preemption laws, 581, 582
- Pregnancy
complications of, 194–195
exposure before, and fertility, 172, 174t–175t
exposure during (*See* Maternal exposure, during
pregnancy; Prenatal exposure)
loss of (*See* Spontaneous abortion)
smoking after (*See* Maternal smoking)
smoking before, and fertility, 170
smoking during (*See* Maternal smoking, during
pregnancy)
- Premenopausal women, breast cancer risk in, 447–449,
450t–453t, 452–454, 456t–465t, 466–470, 474f, 477–478
- Prenatal exposure, 170, 171t, 210, 670
and acute otitis media, 281
and airway development, 47
and asthma, 46–47, 363, 374. *See also* Asthma in children
and atopy/allergies, 263–265, 375–376, 379–380, 381t–
382t, 382, 383f, 384
and cancer in children, 221, 224–225, 226t–241t
and congenital malformations, 205, 206t–209t, 208–209
developmental effects of, 169–171, 210–211, 212t–217t
and infant death, 179
and low birth weight, 198–199, 200t–204t, 204–205
and LRIs in children, 277–280
and lung development in utero, 262–263, 267, 291, 292,
385
and lung function in children and infants, 47, 385,
390–393, 398–399
perinatal outcomes from, 167, 168t–169t, 169–171, 171t
and postnatal exposure, 140, 221, 278
and preterm delivery, 194–195, 196t–197t
and respiratory damage, mechanisms of, 46, 49
and respiratory illness in children, 401
and respiratory symptom prevalence in children, 329,
352–353, 354–355
and SIDS, 50–51
and spontaneous abortion, 176–178, 176t–177t
- Preterm delivery, 194–195, 242
epidemiologic evidence, 195, 196t–197t
- Preterm infants, respiratory symptoms in, 263, 289, 391
- Prevalence (of exposure). *See* Secondhand smoke exposure
prevalence
- Prisons, 154, 586, 628–629
- Pritchard, Raymond, 581
- Private sector, smoking restrictions in, 578, 587–588
- Pro-Children Act of 1994*, 586, 630
- Proposed Identification of Environmental Tobacco Smoke as a
Toxic Air Contaminant* (Cal/EPA 2005), 584
- Protein adducts, 111, 112, 113
- Psychiatric facilities, 626, 627
- Public attitudes
toward acceptability of smoking, 578, 580, 613
toward secondhand smoke, 588–589, 589t, 592, 669–670
and support for smoking restrictions, 580, 581, 582,
588–589, 592
toward smoking restrictions, 588–589, 590t–591t, 592,
593t, 595, 595t–597t, 615
and smoking restriction laws, 578, 580, 582
- Public education, 154
and compliance with smoking restrictions, 609
for home smoking restrictions, 138, 620–621, 624–626
and support for smoking restrictions, 578, 580, 582
- Public Health Service, 669
- Public places. *See also specific type of place*
exposures in, 135–136, 145, 154, 158, 199
smoking restrictions, 134, 576, 578–586
history of, 571, 572t–575t, 576–578
public support for, 588–589, 590t–591t, 592, 593t, 594,
593t–595t
- Public policy approaches, 154, 598–634, 669. *See also*
Smoking restriction policies
- Public transportation, interstate, 631–632
- Publication bias, 21–22, 290–291
in breast cancer risk research, 471, 476f
in coronary heart disease research, 520–521
definition of, 520
in lung cancer risk research, 443–444, 445
in wheeze research, 353–354

PubMed database. *See* Medline search
 Puerto Ricans, 650
 Pyrene, 34
 Pyridine, 545

Q

Questionnaires, 18, 129, 130–131
 biomarker validation of, 18, 111, 130, 131
 misclassification/self-report bias in, 19
 COPD studies, 562
 coronary heart disease studies, 513, 515
 lung cancer risk studies, 19, 444–445, 485, 515
 respiratory effects studies, 539
 Quinones, 32

R

Racial and ethnic variations. *See also specific group*
 beliefs about secondhand smoke, 588
 cotinine half-life, 101
 endothelial-dependent vasodilation, 55
 exposure prevalence, 650
 cotinine level trends, 132, 133, 134t–135t, 135–134
 home smoking restriction prevalence, 619
 infant mortality, 179
 lipid profiles in children, 57
 nicotine levels in hair, 108
 protein adduct levels, 112
 smoking during pregnancy, 134
 support for smoking restrictions, 589, 590t–591t, 593t,
 594, 595t–596t
 workplace smoking restrictions coverage, 601, 606f
 Radioimmunoassay (RIA), 101, 104t–106t
 Railroad workers, 143
 Recurrent otitis media (ROM), 293
 evidence review, 293, 294t–304t, 300, 307f
 Regional variations
 exposure prevalence, 154–155, 158
 of children at home, 137
 home smoking restrictions, 617, 618t, 619t
 housing, 91
 public support for smoking restrictions, 589, 588t–589t,
 592, 593t, 594, 595t–597t
 workplace smoking restrictions
 compliance, 605, 608t
 coverage, 599, 601f, 602t
 Regulations. *See also* Clean indoor air laws; Laws
 federal, 578, 584–586
 state smoking restriction, 582–584
 Reliability, of questionnaire assessments, 18
 Removal rate, 96, 636
 Reperfusion injury, 59

Reproductive effects, 163–233. *See also* Fertility; Pregnancy
 conclusions, 13, 163, 168t–169t, 670
 by exposure period, 169–171, 171t
 implications, 173
 Research methods, for population exposures, 83, 129–132.
 See also specific method
 Respirable particulate matter (RPM), 93–95
 concentrations
 correlations with other atmospheric markers, 93–94,
 94t, 95
 models assessing, 97, 98t
 in hospitality venues, with smoking restrictions, 609
 and inflammation, 253
 sensitivity of, 95f
 Respirable suspended particles (RSP), 97, 98t
 Respiratory effects. *See also* Lung development; Lung
 function; Respiratory illnesses; Respiratory symptoms;
 specific illness or symptom
 in adults, 539–563, 670
 biologic basis, 46–52, 512, 519, 528–530
 conclusions, 22–23, 539, 540t–541t, 562–563
 in children, 6–7, 46, 140, 261–401, 561
 conclusions, 21, 399, 652
 evidence review methods, 254–255
 implications, 401
 mechanisms, 46–52, 262–265
 Respiratory function. *See* Lung function
*Respiratory Health Effects of Passive Smoking: Lung Cancer and
 Other Disorders* (USEPA 1992), 555
 Respiratory illnesses, 45. *See also* Respiratory effects;
 Respiratory symptoms; *specific illness*
 in adults, 555–562
 conclusions, 539, 541t
 and nasal irritation, 546
 lower (*See* Lower respiratory illnesses)
 mechanisms, 46–52
 conclusions, 52, 65
 implications, 66
 limitations of studies, 51–52
 susceptible populations, 135
 upper (*See* Upper respiratory illnesses)
 Respiratory infection
 in children, 6, 49, 180, 280, 352
 viral, 279, 362, 363
 mechanisms, 49
 Respiratory symptoms, 547–555. *See also specific symptom*
 in adults, 547–555
 acute, 547, 548t–549t, 552–553
 chronic, 547, 549, 550t–552t, 552, 553
 conclusions, 539, 540t, 553
 implications, 553
 in children, prevalence of, 310–355
 age factors, 310, 327, 329
 conclusion and implications, 355
 evidence review, 310–355, 312t–318t
 evidence synthesis, 354–355

- prenatal and postnatal exposure and, 329, 352–353
 - under 11 years of age, 327, 354t
- with workplace smoking restrictions, 605
- Respiratory tract
 - cancers, 446, 480–482
 - carcinogens, 30, 32, 33
 - structure and function, 46–47
- Restaurant associations, 577, 583
- Restaurants
 - exposure in, 136, 145
 - legal remedies, 633
 - nicotine concentrations, 145, 152t–153t, 155f, 641
 - secondhand smoke concentrations, 602
 - of workers, 589, 599, 602–604
 - smoking restrictions
 - and air quality, 609
 - and beliefs about acceptability of smoking, 613
 - compliance with, 605, 607–608
 - economic impacts, 613–616
 - and exposure reduction, 609
 - history of, 578, 579f, 579, 581
 - public support for, 588, 589, 590t
 - smoking/nonsmoking areas, 145, 152t–153t, 588, 589, 590t, 642, 643, 645
- Restaurant workers, 589, 599, 601, 602–603, 605
- Rhinitis, atopic/allergic. *See also* Hay fever; Nasal allergies
 - in adults, 546
 - in children, 356, 367–368, 376, 380, 382–383
 - mechanisms, 51
- Risk, 10
- RPM. *See* Respirable particulate matter
- RSP. *See* Respirable suspended particles
- Russia, lung cancer study in, 428t–429t, 487–488

S

- Saliva cotinine assays, 107
- School Health Policies and Programs Study (SHPPS), 630–631
- Schools, 630–631
- Scopoletin, 94t, 95, 95f, 96
- Scotland
 - lung cancer risk study, 426–427
 - lung function in adults, 554
 - nicotine in food study, 109
 - respiratory symptom prevalence in children, 317
- Secondhand smoke
 - carcinogenicity of, 6, 30–45, 43f, 561, 562, 563
 - carcinogens in, 30, 32–33
 - airborne concentrations, 31t–32t
 - human uptake studies, 34, 39–42, 35t–39t, 40t
 - characteristics of, 9, 10, 95, 87, 93
 - classification of
 - as Group A carcinogen, 6, 576, 578
 - as toxic air contaminant, 571–572

- definitions of, 9, 85
- movement in indoor environments, 85, 86–92
- public attitudes toward, 588–589, 589t, 592, 669–670
 - and support for smoking restrictions, 579, 580, 582
- toxicology of, 29–66
 - implications, 66
- Secondhand smoke concentrations. *See also* Atmospheric markers; *specific marker or component*
 - assessment models, 85, 86, 96, 99, 635–636
 - factors affecting, 11–12, 85, 86, 87, 88, 93, 131
 - in homes, 140–141
 - of smokers, 140, 141ff, 142t–143t
 - ventilation systems and, 86, 91–92
 - in hospitality venues, 590, 592
 - variation across settings, 131
 - ventilation systems and, 86–92
- Secondhand smoke exposure
 - atmospheric markers of (*See* Atmospheric markers)
 - average daily duration of, 136
 - biomarkers of (*See* Biomarkers)
 - in children (*See* Child exposures)
 - classification of, 11–13
 - conclusions, 4t, 17
 - definition of, 85
 - health effects, 3–8, 653, 654
 - conclusions, 3–8, 4t–5t, 6t, 18, 19–23
 - reports, 3–8, 7t
 - major conclusions, 11
 - misclassification of (*See* Misclassification)
 - models of (*See* Exposure models)
 - reduction of, and asthma severity, 370, 374
 - safe level of, 18, 65
 - sites of, 12–13, 135–136, 154 (*See also specific site*)
- Secondhand smoke exposure assessment, 11–13, 12f, 85–114, 129–132
 - and air movement indoors, 85, 86–92
 - conclusions, 19, 114
 - methods, 11–13, 85, 129–132 (*See also specific method*)
 - past exposures, 114, 129, 130
- Secondhand smoke exposure control, 571–650
 - conclusions, 18, 23, 649
 - implications, 649–650
 - legal approaches to, 632, 633, 634–635
 - policy approaches to (*See* Smoking restriction policies)
 - technical approaches to, 635–649 (*See also* Air cleaning systems; Exposure models; Smoking areas; Ventilation)
 - effectiveness of, 640
- Secondhand smoke exposure prevalence, 129–158, 669
 - assessment methods, 129–132
 - conclusions, 17, 20, 158
 - estimates, 132–155, 650
 - national trends, by cotinine measurements, 132–133, 133, 134t–135t, 135
 - by site of exposure, 135–154
 - evidence synthesis, 154–155

- Self-reports. *See* Questionnaires
- Semiquinones, 33
- Separation strategies. *See also* Smoking areas
effectiveness of, 639–640
- Service workers, workplace smoking restriction coverage, 599, 601, 604f
- SES. *See* Socioeconomic status
- Shanghai (China)
breast cancer study, 470, 477
lung cancer study, 432t–433t, 434, 438t, 442t, 491–492, 494
nasopharyngeal carcinoma study, 481–482
- Shimp v. New Jersey Bell Telephone Co.* (1976), 634
- Sidestream smoke, 9, 30, 32–34, 45, 83
carcinogenicity studies, 33–34
carcinogens in, 30, 31t–32t, 32–33
- SIDS. *See* Sudden infant death syndrome
- Singapore
allergic rhinitis study, 546
lung cancer study, 432t–433t, 491–492, 493
- Sink effects, 89
- Sinus disease. *See* Nasal and sinus disease
- Sites of exposure, 12–13, 135–136, 154. *See also specific site*
- 16 Cities Study, 96
- Skin-test reactivity, in children, 375–376, 380, 381t–382t, 383f, 384f
- Small for gestational age (SGA), 168t–169t, 171t, 198, 200t–204t
- Smoke. *See also* Mainstream smoke; Secondhand smoke; Sidestream smoke
characteristics of, 9, 32–33, 87, 113
- Smoke-free policies. *See also* Smoking restriction policies
campus, 631
home (*See* Home smoking restrictions)
workplace (*See* Workplace smoking restrictions)
- SmokeLess States program, 580–581
- Smoke plume, dynamics of, 87
- Smokers. *See also* Smoking status
cotinine half-life in, 101, 104t–105t
homes of, nicotine concentrations in, 140, 141f, 142t–143t
in homes with smoking restrictions, 603, 617, 618
living with, as exposure indicator, 130, 137, 138 (*See also* Spousal smoking)
misclassification of, 19
pregnant (*See* Maternal smoking, during pregnancy)
- Smoker-years, 454
- Smoking
by adolescents, 626
beliefs about acceptability of, smoking restrictions and, 613
and breast cancer risk, 446–480
and cancer risk, 423, 446
and cervical cancer risk, 482
and coronary heart disease, 52–65
and fertility, 171–173
health effects of, and association of exposure with disease, 10
hospital smoking restrictions and, 626–628
and lung cancer, 423
and nasopharyngeal carcinoma, 480–482
by parent (*See* Maternal smoking; Parental smoking; Paternal smoking)
before pregnancy, and fertility, 167, 169–170
during pregnancy (*See* Maternal smoking, during pregnancy)
prevalence
in adults, 587, 612
home smoking restrictions and, 625–626
in military personnel, 586
workplace smoking restrictions and, 611–613, 626
by spouse (*See* Spousal smoking)
- Smoking and Health: A Report of the Surgeon General* (1979).
See Surgeon General's report (1979)
- Smoking areas
aircraft, 584–585
airport, 97, 631
design of, 635, 636–637, 638–639, 641, 643
effectiveness of, 640–649
restaurant, nicotine concentrations in, 145, 152t–153t
in VA facilities, 626
- Smoking bans. *See also* Smoking restriction policies
in bars, 581, 589, 592, 593t, 594
effectiveness of, 154, 632–642, 646–647, 649–650
and exposure reduction, 609
in hospitals, 626–627, 637
in prisons, 628–629
in private sector workplaces, 587
in restaurants, public support for, 588–589, 590t
and smoking behavior, 612–613, 625–626
- Smoking cessation
at colleges, 631
home smoking restrictions and, 625–626
hospital smoking restrictions and, 626
maternal, and LRIs in children, 290
in military personnel, 586
in parents, interventions for, 620, 624–625
workplace smoking restrictions and, 612–613
- Smoking reduction
home smoking restrictions and, 625–626
in military, 586
workplace smoking restrictions and, 612–613
- Smoking restriction policies, 154, 155, 571–650
on aircraft, 584–585
in bars, 581, 582–583, 584
compliance with, 605, 607–609
public support for, 588, 589, 591t, 592, 593t
and beliefs about acceptability of smoking, 613
in colleges, 631
compliance with, 605, 607–609
conclusions, 649
in day care settings, 630
effectiveness studies, 640–647
federal, 578, 584–586, 630
in federal facilities, 578, 586, 626, 628

- history of, 571–578
 - milestones in, 572t–575t
 - in homes (*See* Home smoking restrictions)
 - in hospitals, 626–628
 - in hotels, 632
 - implications, 649–650
 - in institutional settings, 626–630
 - in interstate public transportation, 631–632
 - legal (court) approaches to, 634–635
 - local ordinances, 572t–575t, 578–582, 579f
 - in malls, 594, 596t
 - in military, 586
 - in multiunit housing, 632–633
 - nursing homes, 629–630
 - outdoor, 633–634
 - in prisons, 628–629
 - public attitudes toward, 588–589, 590t–591t, 592, 593t, 594, 595t–597t, 669
 - in public places, 134, 598, 623, 669, 670, 671 (*See also specific type of place*)
 - history of, 572t–575t, 578–586
 - public support for, 588–589, 590t–591t, 592, 593t, 594, 595t–596t
 - in restaurants
 - history of, 578–579, 579f, 581
 - public support for, 588–589, 590t, 592
 - restaurants with, nicotine concentrations in, 145, 152t–153t
 - in schools, 630–631
 - in sports arenas, 594, 595t
 - in state government worksites, 582
 - statewide, 572t–576t, 578–584, 583f
 - tobacco industry and, 577–578, 581, 584, 585–586
 - in workplaces (*See* Workplace smoking restrictions)
 - workplaces with
 - exposure in, 141–145, 146t–149t, 148f, 149f, 154, 602–605
 - nicotine levels after, 642
 - prevalence of, 142, 587–588
- Smoking status
- and home smoking restriction prevalence, 616, 618t, 619
 - and support for smoking restrictions, 589, 589t–591t, 593t, 593t–596t
 - and workplace smoking restrictions coverage, 601–602, 606t
- Social Climate Survey of Tobacco Control (2001), 588
- Social norms. *See also* Public attitudes
- changes in, smoking restrictions and, 580, 589, 613, 669–670
- Socioeconomic status. *See also* Educational level;
- Occupation(s)
- as confounding factor, 22, 22f
 - and exposure prevalence, 154, 511, 512
 - and home exposure prevalence in children, 137, 620
 - and home smoking restriction prevalence, 617, 619, 619t
 - and maternal exposure during pregnancy, 140
 - and smoking during pregnancy, 139
 - and support for smoking restrictions, 588–589, 590t–591t, 592, 593t, 594, 595t–597t
- Solanesol, 94t, 95, 95f, 96
- Sorption, 97
- Source control, 636, 637
- Source strength, 85, 130
- South Africa, 283, 354
- Specific airway conductance, in infants, 391
- Specificity, 10
- Sperm quality, 166, 168
- Spontaneous abortion, 176–178, 176t–177t, 242
- Sports arenas, smoking restrictions in, 588–589, 594, 595t
- Spousal smoking. *See also* Home exposures
- and breast cancer risk, 448–449, 450t–453t, 452–455, 464–480
 - and cervical cancer risk, 482–483
 - and COPD risk, 571
 - as exposure indicator, 17, 126
 - and lung cancer risk, 6, 423, 426–427, 428t–433t, 434, 435, 436t, 445, 484, 485–497
 - and nasopharyngeal carcinoma, 480–482
 - and NNK levels, 40–41
 - policy approaches toward, 598
- Staron et al. v. McDonald's Corp.* (1995), 634
- States. *See also specific state*
- government worksite smoking restrictions in, 582–584
 - local smoking restriction ordinances and, 578–582
 - preemption laws, 581, 582
 - smoking restriction laws, 572t–575t, 578–584, 583f
 - multiunit housing, 632
 - public support for, 588–589
 - tobacco control programs, 580
 - tobacco-producing, 592, 594
- State variations
- in child home exposure prevalence, 137
 - in home smoking restriction prevalence, 599, 600t
 - in public support for smoking restrictions, 589, 592
 - in smoking restriction prevalence, 670
 - in workplace smoking restriction coverage, 599, 600t
- Steel workers, 30
- Steinfeld, Jesse, 3, 584–585, 669
- Stockholm Heart Epidemiology Program, 511–512
- Stomach cancer, 446
- Stroke, 527, 528t, 529
 - conclusions, 532
 - evidence synthesis, 531–532
 - mortality, 527
- Styrene, 96
- Subclinical vascular disease, 529–530. *See also*
- Atherosclerosis
- Substance abuse treatment settings, 627, 628
- Sudden death, in children, 180
- Sudden infant death syndrome (SIDS), 180–194, 242
- airway development in, 251
 - apnea, 51

conclusions, 11, 12, 13, 52, 194
 epidemiologic evidence, 180–181, 182t–191t, 190–193
 mechanism of, 50–51
 Supreme Court, 629
 Surgeon General’s report(s)
 causal association criteria, 9–10
 conclusions, 3–6, 4t–5t, 6t
 impact on tobacco control initiatives, 571
 on secondhand smoke, 3
 Surgeon General’s report (1964), 29, 423, 669
 causal association criteria, 9, 10
 Surgeon General’s report (1972), 3, 571, 669
 Surgeon General’s report (1975), 3
 Surgeon General’s report (1979), 3
 Surgeon General’s report (1982), 3
 Surgeon General’s report (1983)
 coronary heart disease, 519–520
 Surgeon General’s report (1984), 3, 373
 Surgeon General’s report (1986), 3, 6, 129, 158, 167, 509, 669
 on bias in exposure estimates, 20
 conclusions, 6, 6t, 7, 571
 impact of, 571, 576, 578–579
 on lung cancer and secondhand exposure, 411, 578
 on lung growth in children, 373
 on mainstream and secondhand smoke, 10, 83
 on odor and nasal irritation, 531
 on respiratory illness in children, 249
 Surgeon General’s report (1989), on public attitudes toward
 secondhand smoke, 587
 Surgeon General’s report (2000), on smoking bans, 609
 Surgeon General’s report (2001)
 on breast cancer risk, 446–447
 on coronary heart disease, 495–498, 509, 511–512,
 576–577
 on developmental and reproductive effects, 167, 169t
 Surgeon General’s report (2004), 8, 10, 29, 670
 on breast cancer risk, 446
 causal association criteria, 9, 10
 on maternal smoking during pregnancy, 167
 on SIDS, 180
 on sperm quality in smokers, 172
 Surgeon General’s report (2006), 7–8
 causal association classification hierarchy, 10, 10t
 causal association criteria, 9–10
 companion database, 8–9
 definitions and terminology, 9
 evidence evaluation, 9–11
 methodologic issues, 11–17
 organization of, 8
 preparation of, 8–9
 Susceptible populations, 139–140, 670
 Sweden
 asthma studies
 in adults, 556
 in children, 354, 355, 368
 diet of exposed versus unexposed women, 517

LRIs in children study, 268, 289
 lung cancer risk study, 438, 487, 488–489
 myocardial infarction study, 511–512, 516t
 respiratory symptom prevalence in children, 352
 spontaneous abortion study, 176–178
 Switzerland
 acute otitis media study, 281
 asthma in adults study, 556
 breast cancer risk study, 15, 454–455
 COPD study, 559
 diet of exposed versus unexposed women, 504
 Sympathetic nervous system, 63
 Systematic reviews
 acute LRIs in children, 267–268
 allergic sensitization, 375–376
 respiratory illness in children, 261, 266

T

Taiwan
 lung cancer studies, 434, 492–493
 nasopharyngeal carcinoma study, 481
 respiratory symptom prevalence in children study, 310,
 318–319, 352
 T cells, in airways, 48, 251, 252
 Tea, 107
 Technetium^{99m}, 543
 Technical approaches (to control), 635–649. *See also* Air
 cleaning systems; Exposure models; Smoking areas;
 Ventilation
 effectiveness of, 640–649
 Tenants, 632–633
 Tennessee, 581
 Terminology, 9
 Texas, smoking restrictions in, 580, 614
 Thermophoresis, 636
 Thiocyanate, 100–101, 102t–103t
 in mothers and infants, 221
 Thioethers, 41
 Third National Health and Nutrition Examination Survey.
 See National Health and Nutrition Examination Survey,
 Third
 *Third National Report on Human Exposure to Environmental
 Chemicals* (CDC 2005), 606, 670
 Thompson, Tommy, 588
 Thrombosis, 53, 54–57, 64
 Tobacco control measures. *See* Secondhand smoke exposure
 control
 Tobacco control movement, 579–581
 Tobacco control program(s)
 in California, 579–580, 610
 national, 671
 state, 579–580
 Tobacco-free campus policies, 587–588, 628, 660

Tobacco industry

- on economic impact of smoking restrictions, 575, 611
 - and EPA report on health effects of passive smoking (1992), 15, 576
 - lawsuit against, 634
 - and lung cancer research, 443–444, 445
 - and smoking restriction initiatives, 577, 581, 584, 586, 612–613
 - and ventilation, 637, 638
- Tobacco Institute, 577
- 2-Toluidine, 30
- Tonsillectomy, 293, 300t, 303t, 306t, 309
- Tourism, smoke-free restaurant laws and, 615
- Toxic air contaminant, classification of secondhand smoke as, 584
- Toxic compounds (in smoke), 95–96
- Tracer gas testing, 92
- Tracers. *See* Atmospheric markers
- Trains, 632
- Tucson (Arizona)
- asthma onset in children, 360, 363
 - wheeze in early childhood, 267, 356
- Turbulence, 87

U

- United Airlines, 585
- United Kingdom, 138
- asthma in children study, 366, 367–368
 - breast cancer studies, 454
 - COPD study, 560
 - cotinine study, 110
 - hearing loss studies, 308, 309
 - LRIs in children study, 283, 289, 290
 - lung function in adults study, 554
 - reproductive and perinatal effects study, 167, 168t
 - respiratory symptom prevalence in children study, 311, 319, 329
 - smoking/nonsmoking areas in bars, 641, 642–643, 643t
 - socioeconomic characteristics of exposed *versus* unexposed persons, 517
 - stroke study, 527
 - wheeze in children study, 356, 360, 364, 367–368
- United Kingdom National Case-Control Study Group, 454
- Upper respiratory illnesses
- cancers, 480–482
 - combined with LRIs, in children, 272t, 283, 287t, 288t
- Urine cotinine assays, 107
- U.S. Public Health Service, 669
- Utah, 133, 138, 582, 592, 599, 617, 631
- UVPM (ultraviolet-absorbing particulate matter), 95, 99
- sensitivity, 95, 96f

V

- VA. *See* Department of Veterans Affairs
- Validation, of questionnaire assessments, 18, 113, 130, 131
- Vancouver (Canada), smoking/nonsmoking areas in bars in, 643–644, 644f
- Vascular disease. *See also specific disease*
- subclinical, 529–531, 670
- Vascular endothelium, 54. *See also* Endothelial dysfunction
- Vasodilation, endothelial-dependent, 54–56, 56f
- Ventilation, 85, 86–92, 635–639
- conclusions and implications, 92
 - controlled building, 88
 - control operations, 89–91
 - dilution, 88–89, 639–640, 646
 - displacement, 88, 89, 639
 - effectiveness as exposure control, 92, 638, 646–647, 649, 670
 - of homes, 86, 91–92
 - local exhaust, 88
 - natural, 86, 91
 - outdoor air delivery in, 89–90, 90f
 - rates, and time of year, 647, 648f
 - standards, 89, 90f, 90t, 646, 648
- Ventilation codes, 89
- Vermont, smoking restrictions in, 578, 592, 629
- Veterans Health Care Act of 1992, 626
- Viral infections, respiratory, 291, 374, 375
- Vitamin C. *See* L-Ascorbic acid

W

- Washington state
- cervical cancer study, 483
 - prison smoking restrictions, 628–629
 - workplace smoking restrictions, 582, 584, 592
- Western New York Exposures and Breast Cancer Study, 468–469, 474–475
- West Virginia, 580, 592
- Wheeze
- in adults, 547, 549, 550t–552t, 553
 - in children
 - age factors, 356, 366–367, 374
 - and asthma onset, 355–375
 - evidence synthesis, 374–375
 - incidence studies, 355, 356, 357t–362t, 360, 363, 363f, 374
 - prevalence studies, 355, 357t–360t, 364, 365t–366t, 366–367, 367f
 - prognosis studies, 355, 357t–360t, 360, 361t, 363
 - relevant studies, 355–356, 357t–360t
 - severity studies, 355, 368, 369t–373t, 374
- atopic, 367–368, 374
- classification of (phenotypes), 267
- conclusions, 400
- incidence, 401

- prevalence, 401
- school-age, prevalence of
 - conclusions, 355
 - evidence review, 319, 326, 329, 330t–339t, 340f, 353, 353t
 - evidence synthesis, 354–355, 374–375
 - publication bias, 353–354
 - relevant studies, 311, 312t–318t
 - under 11 years of age, 327, 354t
- severity, 401
- young, 265, 267, 356, 360, 363–364, 375, 401
 - evidence review, 268, 269t–278t, 282t, 283, 284t–288t, 288
 - mechanism, 265, 290–291
- in infants, 289, 356, 363–364, 366–367, 401
- White-collar workers. *See also* Occupation(s)
 - workplace smoking restriction coverage, 599, 604f
- Whites. *See also* Racial and ethnic variations
 - beliefs about secondhand smoke, 588
 - cotinine half-life in, 101
 - cotinine level trends, 133, 134t–135t
 - home smoking restriction prevalence, 619
 - support for smoking restrictions, 589, 590t, 594
- Women. *See also* Gender variations; Maternal exposure; Maternal smoking; Pregnancy; Spousal smoking
 - antioxidant levels, 62
 - beliefs about secondhand smoke, 588
 - breast cancer in (*See* Breast cancer)
 - bronchial hyperreactivity, 543, 557
 - carcinogen uptake, 40–42
 - cervical cancer in (*See* Cervical cancer)
 - Chinese, 469–470, 491–496
 - COPD studies, 560, 561
 - coronary heart disease studies, 55, 509, 576–577
 - cotinine half-life in, 101
 - exposed *versus* unexposed, diet and behavior of, 444, 502, 503
 - exposure prevalence, 140, 634
 - lung cancer risk, 423, 434, 439–440
 - case control studies, 485–497
 - cohort studies, 426t–427t, 426–427, 485–486
 - conclusions, 423, 424t–425t
 - nasopharyngeal carcinoma risk, 481
 - support for smoking restrictions, 588–589
 - workplace smoking restriction coverage, 598
- Women and Smoking* (2001). *See* Surgeon General's report (2001)
- Working Well Trial, 503
- Workplace(s). *See also specific type of workplace*
 - as exposure site, 135–136, 170–171
 - with high exposure potential, 600–603
 - nicotine concentrations, 140, 143–145
 - by smoking policy, 146t–151t, 148f, 149f, 644–646, 646f
 - with smoking restrictions, 609–610
 - without smoking restrictions, 151f
 - size, and smoking restrictions, 587
 - with smoking restrictions (*See also* Workplace smoking restrictions)
 - exposure in, 141–145, 146t–151t, 148f, 149f, 154, 609–610, 639–647
 - prevalence of, 142, 587–588
- Workplace exposure, 154, 158
 - and asthma onset in adults, 556
 - and breast cancer, 436, 446, 449, 450t–453t, 452, 454–455, 456t–465t, 467–471, 474, 477, 479
 - and coronary heart disease risk, 519
 - and lower birth weight, 194
 - and lung cancer, 435, 436t–438t, 438–439, 440t, 486–496, 603–605
 - and nasopharyngeal carcinoma, 481
 - nicotine concentrations, by smoking policy, 144f, 144t–147t, 145f
 - to non-tobacco carcinogens, 435
 - and odor annoyance and nasal irritation, 545–546
 - prevalence, 135–136, 139, 141–145, 154, 423
 - settings with high potential for, 602–605
 - smoking restrictions and, 141–145, 146t–151t, 148f, 149f, 154, 609–610, 640–649
- Workplace smoking restrictions, 571, 578–588, 598–616, 635
 - See also specific type of workplace*
 - compliance with, 605–609, 642
 - effectiveness criteria, 598, 609–610
 - effectiveness studies, 640–649
 - effects, 609–613
 - air quality, 609
 - beliefs about acceptability of smoking, 613
 - economic, 613–616
 - exposure reduction, 609
 - health outcomes, 610–611
 - smoking behavior, 611–613
 - tobacco industry on, 577
 - exposure and, 141–145, 146t–151t, 148f, 149f, 154, 609–610, 640–649
 - forms, 598
 - in government facilities, 578, 586
 - history of, 571–588
 - laws mandating
 - federal, 578, 584–586, 634
 - local, 572t–576t, 578–584, 579f
 - national, outside U.S., 642
 - state, 572t–576t, 582–584, 583f
 - nicotine concentrations by type of, 146t, 148f–149t, 149f
 - prevalence, 142, 587–588, 598–602
 - in private sector, 587–588, 598–602
 - public support for, 577, 594, 597t
 - reasons for, 598
- World Health Organization (WHO)
 - International Consultation on Environmental Tobacco Smoke and Child Health: Consultation Report* (WHO 1999), 261
 - European Center, on indoor air rights, 637–638
 - on lung function in children, 385
 - on reproductive/perinatal effects, 167, 169t
 - Tobacco or Health: A Global Status Report* (WHO 1997), 319

